≡ Risteys
R14

Documentation Changelog GitHub Contact & Feedback

Sickle-cell disorders

DOID EFO Endpoint Browser PheWeb

D3_SICKLECELLDIS

obsolete_sickle cell disease: ['A blood disorder characterized by the appearance of sickle-shaped red blood cells and anemia.']

Suggest a new description

Endpoint definition

↥

Report an error or suggest an improvement for this endpoint codes

Endpoint definition steps

FinnGen

Phenotype data

519870

1. Apply sex-specific rule

None

519870

2. Check conditions

None

519870

3. Check pre-conditions, main-only, mode, registry filters

Registry filters:

  • Hospital discharge: ICD-10 — D57
  • Hospital discharge: ICD-9 — 282[5-6]
  • Cause of death: ICD-10 — D57
  • Cause of death: ICD-9 — 282[5-6]

2 out of 7 registries used, show all original rules.

98

4. Check minimum number of events

None

98

5. Include endpoints

None

98

6. Filter based on genotype QC (FinnGen only)

74

Control definitions (FinnGen only)

Control exclude
D3_HAEMOLYTICANAEMIA

Extra metadata

Level in the ICD hierarchy
3
First used in FinnGen datafreeze
DF2
Parent code in ICD-10
D55-D59
Name in latin
Morbi meniscocytici

Case counts by codes

↥

FinnGen case counts by registry codes:

generic upset plot

Upset plot

Full data table

Summary Statistics

↥

-FinRegistry-

Key figures

All Female Male
Number of individuals
Whole population 754 385 332
Only index persons 575 317 258
Unadjusted period prevalence (%)
Whole population 0.01 0.01 0.01
Only index persons 0.01 0.01 0.01
Median age at first event (years)
Whole population 52.37 54.03 52.53
Only index persons 56.62 57.36 55.71

-FinnGen-

Key figures

All Female Male
Number of individuals 74 38 36
Unadjusted period prevalence (%) 0.01 0.01 0.02
Median age at first event (years) 60.42 60.79 60.04

-FinRegistry-

Age distribution of first events

-FinnGen-

Age distribution of first events

-FinRegistry-

Year distribution of first events

-FinnGen-

Year distribution of first events

-FinRegistry-

Cumulative Incidence Function

-FinnGen-

Cumulative Incidence Function

No data

CodeWAS

↥

CodeWAS is a tool for exploring the associations between an endpoint and all of the medical codes and drug codes.

This is a new tool, please reach out using the contact form for feedback and improvement ideas.

First, a cohort is built by matching controls to the endpoint cases using year of birth and sex. Then, a Fisher test is done for all the medical codes and drug codes between the cases and controls of this cohort. Codes are reported in the table below if they have −log10(p-value) ≥ 6.

Matched cohort

Matched cases
98
Matched controls
980
Code
Vocabulary
Description
Odds Ratio
-log10(p)
N matched cases
N matched controls
D57.3
ICD-10 Finland
Sickle-cell trait
+∞
46.6
41
*
N08.2*D57.8
ICD-10 Finland
Glomerular disorders in sickle-cell disorders
+∞
35.6
32
*
N08.2*D89.80
ICD-10 Finland
Immunoglobulin A (IgA) nephropathy
244.9
34.1
33
*
D89.80
ICD-10 Finland
Immunoglobulin A (IgA) deposits in organisms
348.9
27.1
26
*
123
Kela drug reimbursment
Chronic disorders of vitamin D metabolism
50.5
24.7
29
8
JN3AE
NOMESCO Finland
Abdominal ultrasound examination
9.0
23.2
37
62
Z94.0
ICD-10 Finland
Kidney transplant status
148.3
22.7
23
*
138
Kela drug reimbursment
Severe anaemia associated with chronic renal failure
66.2
22.4
25
5
A12AA04
ATC
calcium carbonate; oral
66.2
22.4
25
5
A11CC03
ATC
alfacalcidol; systemic
40.6
22.0
27
9
127
Kela drug reimbursment
Transplant complication
140.1
21.5
22
*
L04AA06
ATC
mycophenolic acid; systemic
49.3
19.6
23
6
KA2AE
NOMESCO Finland
Ultrasound examination transplanted kidney
+∞
19.4
18
*
KAS10
NOMESCO Finland
Allogenic transplantation of kidney from cadaver donor
232.7
19.3
19
*
TK800
NOMESCO Finland
Hemodialysis
65.9
18.8
21
*
KA2AT
NOMESCO Finland
Biopsy of transplanted kidney with ultrasound guidance
+∞
18.3
17
*
Z49.1
ICD-10 Finland
Extracorporeal dialysis
116.5
18.3
19
*
190
Kela drug reimbursment
Lanthanum carbonate, sevelamer and sucroferric oxyhydroxide
217.8
18.2
18
*
PBL10
NOMESCO Finland
Construction of arteriovenous fistula from radial artery
58.2
16.7
19
*
N18.9
ICD-10 Finland
Chronic kidney disease, unspecified
8.5
16.1
24
36
N18.0
ICD-10 Finland
End-stage renal disease
101.8
16.1
17
*
D57.1
ICD-10 Finland
Sickle-cell anaemia without crisis
+∞
16.1
15
*
L04AD02
ATC
tacrolimus; systemic
188.9
16.0
16
*
N08.2
ICD-10 Finland
Glomerular disorders in blood diseases and disorders involving the immune mechanism
188.9
16.0
16
*
V03AE01
ATC
polystyrene sulfonate; oral
54.4
15.7
18
*
JN1AE
NOMESCO Finland
Ultrasound examination of upper part of abdomen
7.5
15.4
26
45
B03XA02
ATC
darbepoetin alfa; parenteral
27.1
13.5
18
8
H02AB04
ATC
methylprednisolone; systemic
5.6
13.3
32
78
TPH15
NOMESCO Finland
Insertion of central venous catheter through external or internal jugular vein
12.3
13.2
24
25
KA1AE
NOMESCO Finland
Kidney ultrasound examination
28.9
13.0
17
7
V03AE03
ATC
lanthanum carbonate; oral
+∞
12.8
12
*
196
Kela drug reimbursment
Paricalcitol and cinacalcet
+∞
12.8
12
*
V03AE02
ATC
sevelamer; oral
148.2
12.8
13
*
M04AA01
ATC
allopurinol; systemic
5.4
12.3
31
78
B03XA01
ATC
erythropoietin; parenteral
74.0
11.9
13
*
137
Kela drug reimbursment
Uraemia requiring dialysis
74.0
11.9
13
*
C09AA02
ATC
enalapril; systemic
4.7
11.8
38
117
TPH04
NOMESCO Finland
Cathetrisation of vein
4.6
11.7
39
123
K57.3
ICD-10 Finland
Diverticular disease of large intestine without perforation or abscess
4.9
11.4
32
88
TPH90
NOMESCO Finland
Removal of fixed intravenous catheter
49.4
11.2
13
*
PG1DE
NOMESCO Finland
Other extensive ultrasound examination of artery
12.2
11.2
20
20
KA3AT
NOMESCO Finland
Biopsy of kidney with ultrasound guidance
67.6
10.9
12
*
J01EE01
ATC
sulfamethoxazole and trimethoprim; systemic
11.1
10.6
20
22
320
Kela drug reimbursment
Lanthanum carbonate, sevelamer and sucroferric oxyhydroxide
122.6
10.6
11
*
H05BX01
ATC
cinacalcet; oral
+∞
10.6
10
*
321
Kela drug reimbursment
Paricalcitol and cinacalcet
+∞
10.6
10
*
C03CA01
ATC
furosemide; systemic
3.9
10.2
52
220
B05DB
ATC
Hypertonic solutions
61.3
9.9
11
*
B05DA
ATC
Isotonic solutions
61.3
9.9
11
*
Z49.0
ICD-10 Finland
Preparatory care for dialysis
61.3
9.9
11
*
205
Kela drug reimbursment
Chronic hypertension
3.9
9.7
43
164
D57.0
ICD-10 Finland
Sickle-cell anaemia with crisis
+∞
9.5
9
*
L04AD01
ATC
ciclosporin; systemic
40.8
9.2
11
*
I15.1
ICD-10 Finland
Hypertension secondary to other renal disorders
55.1
8.9
10
*
Z49.2
ICD-10 Finland
Other dialysis
55.1
8.9
10
*
NA3AA
NOMESCO Finland
Lumbar spine X-ray examination without contrast
5.1
8.7
21
50
TK820
NOMESCO Finland
Peritoneal dialysis
98.1
8.6
9
*
D64.9
ICD-10 Finland
Anaemia, unspecified
4.8
8.1
21
53
L04AX01
ATC
azathioprine; systemic
12.3
8.1
14
13
ZXE20
NOMESCO Finland
More than three and less than five hours
4.3
8.0
24
68
FM1AE
NOMESCO Finland
Standard cardiac ultrasound examination
3.8
7.9
31
107
N08.39*E11.2
ICD-10 Finland
Non-insulin-dependent diabetes mellitus - Diabetic nephropathy
49.0
7.8
9
*
UJD10
NOMESCO Finland
Esophagoscopy, gastroscopy and duodenoscopy
3.4
7.8
40
164
L01XX05
ATC
hydroxycarbamide; oral
27.5
7.7
10
*
R4110
NOMESCO Finland
Physiotherapy
3.3
7.6
41
174
PG5DE
NOMESCO Finland
Ultrasound examination of injection gate to artery or vein with Doppler method
86.3
7.5
8
*
JAK10
NOMESCO Finland
Laparotomy and insertion of peritoneal dialysis catheter
86.3
7.5
8
*
N18.8
ICD-10 Finland
Other chronic renal failure
17.5
7.4
11
7
PBM10
NOMESCO Finland
Closure of arteriovenous fistula of radial artery
+∞
7.4
7
*
N08.2*D89.82
ICD-10 Finland
Nepropathy caused by deposition of the light chain of the immunoglobulins
+∞
7.4
7
*
ZXD30
NOMESCO Finland
Difficulties in perfomrming procedure
8.1
7.4
16
23
WZC10
NOMESCO Finland
Written specialist consultation based on a referral from a dentist or a physician
9.4
7.1
14
17
UJF32
NOMESCO Finland
Coloscopy
3.3
7.0
35
140
C02CA01
ATC
prazosin; oral
12.2
7.0
12
11
ZXD05
NOMESCO Finland
Urgent procedure
3.1
6.9
44
203
XPX08
NOMESCO Finland
Intraoperative flow measurement
43.2
6.9
8
*
L04AA01
ATC
[U] ciclosporin
43.2
6.9
8
*
GD1UA
NOMESCO Finland
Thorax X-ray examination outside radiological department
3.8
6.8
25
82
C08CA01
ATC
amlodipine; oral
3.0
6.7
51
260
TJA35
NOMESCO Finland
Removal of peritoneal dialysis catheter
74.5
6.5
7
*
PG5RT
NOMESCO Finland
PTA of arterio-venous shunt for dialysis
74.5
6.5
7
*
ZXE10
NOMESCO Finland
More than one and less than three hours
3.0
6.4
45
218
D41.0
ICD-10 Finland
Neoplasm of uncertain or unknown behaviour: Kidney
19.6
6.4
9
5
D56.3
ICD-10 Finland
Thalassaemia trait
+∞
6.3
6
*
TPH20
NOMESCO Finland
Insertion of central venous catheter through subclavian or brachiocephalic vein
13.7
6.2
10
8
J01MA02
ATC
ciprofloxacin; systemic
2.9
6.2
47
237
N39.0
ICD-10 Finland
Urinary tract infection, site not specified
3.5
6.2
25
87
R10.4
ICD-10 Finland
Other and unspecified abdominal pain
2.9
6.1
46
231

TimeCodeWAS

↥

TODO / Current known limitations:

  • Only showing the top 300 codes, because showing all (sometimes 20k) makes the page too slow.
  • Legend / how to read the glyphs.
  • Show details (e.g. Fisher or Chi-square test, LR+, etc.) when clicking on a row.
  • Explanation on the underlying data / how the TimeCodeWAS is done (e.g. matched cases / controls, eligibility).
  • Download CSV.
  • No filters and sorters.
  • Limited amount of endpoints (~400) having TimeCodeWAS data.
  • Cross-links to Risteys lab test pages for lab test codes.
OMOP concept
ln(OR)
%cases with code / %controls with code
2×2 table
Outpatient Visit
OP [9202]
8.9e-01
1.4e+00
1.8e+00
5.4e+00
2.0e+00
1.9e+00
2.2e+00
cases:83.33%
controls:67.29%
cases:79.38%
controls:48.50%
cases:43.30%
controls:11.07%
cases:58.76%
controls:0.62%
cases:44.79%
controls:9.52%
cases:84.04%
controls:44.68%
cases:96.39%
controls:75.03%
80
646
16
314
77
469
20
498
42
107
55
860
57
6
40
961
43
92
53
874
79
428
15
530
80
646
3
215
Outpatient Hospital
22 [8756]
1.2e+00
1.5e+00
2.3e+00
—
2.4e+00
2.0e+00
1.4e+00
cases:55.21%
controls:26.56%
cases:26.80%
controls:7.65%
cases:9.28%
controls:1.03%
—
—
cases:10.42%
controls:1.04%
cases:39.36%
controls:7.72%
cases:57.83%
controls:24.39%
53
255
43
705
26
74
71
893
9
10
88
957
—
10
10
86
956
37
74
57
884
48
210
35
651
Internal Medicine
11 [38004456]
1.4e+00
1.8e+00
2.4e+00
1.0e+50
2.3e+00
1.9e+00
1.1e+00
cases:54.17%
controls:21.98%
cases:40.21%
controls:9.82%
cases:17.53%
controls:1.96%
cases:34.02%
controls:0.00%
cases:14.58%
controls:1.76%
cases:38.30%
controls:8.56%
cases:45.78%
controls:21.72%
52
211
44
749
39
95
58
872
17
19
80
948
33
0
64
967
14
17
82
949
36
82
58
876
38
187
45
674
furosemide; oral, parenteral
C03CA01 [21601518]
1.8e+00
1.9e+00
1.8e+00
—
1.9e+00
1.8e+00
1.6e+00
cases:27.08%
controls:5.52%
cases:28.87%
controls:5.58%
cases:10.31%
controls:1.86%
—
—
cases:9.38%
controls:1.55%
cases:26.60%
controls:5.53%
cases:28.92%
controls:7.90%
26
53
70
907
28
54
69
913
10
18
87
949
—
9
15
87
951
25
53
69
905
24
68
59
793
Inpatient Hospital
21 [8717]
9.8e-01
1.4e+00
2.4e+00
—
2.3e+00
1.8e+00
1.2e+00
cases:60.42%
controls:36.35%
cases:40.21%
controls:13.96%
cases:17.53%
controls:1.86%
—
—
cases:14.58%
controls:1.66%
cases:46.81%
controls:12.42%
cases:63.86%
controls:34.26%
58
349
38
611
39
135
58
832
17
18
80
949
—
14
16
82
950
44
119
50
839
53
295
30
566
Nephrology
39 [38004479]
3.8e+00
—
—
1.0e+50
—
—
4.2e+00
cases:22.92%
controls:0.63%
—
—
—
—
cases:9.28%
controls:0.00%
—
—
—
—
cases:36.14%
controls:0.81%
22
6
74
954
—
—
9
0
88
967
—
—
30
7
53
854
Emergency Room Visit
ER [9203]
1.1e+00
1.3e+00
2.6e+00
1.0e+50
1.5e+00
1.8e+00
9.9e-01
cases:61.46%
controls:34.06%
cases:38.14%
controls:14.06%
cases:20.62%
controls:1.86%
cases:14.43%
controls:0.00%
cases:7.29%
controls:1.66%
cases:42.55%
controls:11.17%
cases:60.24%
controls:36.00%
59
327
37
633
37
136
60
831
20
18
77
949
14
0
83
967
7
16
89
950
40
107
54
851
50
310
33
551
losartan; oral
C09CA01 [21601824]
2.0e+00
2.2e+00
—
—
1.8e+00
1.7e+00
1.6e+00
cases:17.71%
controls:2.71%
cases:15.46%
controls:2.07%
—
—
—
—
cases:5.21%
controls:0.93%
cases:14.89%
controls:3.13%
cases:21.69%
controls:5.34%
17
26
79
934
15
20
82
947
—
—
5
9
91
957
14
30
80
928
18
46
65
815
methylprednisolone; oral, parenteral
H02AB04 [21602732]
1.7e+00
—
—
—
—
2.6e+00
2.4e+00
cases:9.38%
controls:1.77%
—
—
—
—
—
—
—
—
cases:6.38%
controls:0.52%
cases:15.66%
controls:1.63%
9
17
87
943
—
—
—
—
6
5
88
953
13
14
70
847
enalapril; oral, parenteral
C09AA02 [21601786]
1.7e+00
1.5e+00
—
—
—
1.4e+00
1.5e+00
cases:21.88%
controls:4.90%
cases:14.43%
controls:3.52%
—
—
—
—
—
—
cases:12.77%
controls:3.34%
cases:16.87%
controls:4.18%
21
47
75
913
14
34
83
933
—
—
—
12
32
82
926
14
36
69
825
Thorax X-ray examination
GD1AA [2001303617]
1.1e+00
1.5e+00
—
1.0e+50
—
1.7e+00
1.8e+00
cases:14.58%
controls:5.21%
cases:12.37%
controls:3.10%
—
—
cases:7.22%
controls:0.00%
—
—
cases:10.64%
controls:2.09%
cases:26.51%
controls:5.81%
14
50
82
910
12
30
85
937
—
7
0
90
967
—
10
20
84
938
22
50
61
811
Pharmacy visit
OMOP4822462 [581458]
8.6e-02
9.7e-01
8.7e-01
2.0e+00
7.6e-01
2.3e+00
1.0e+50
cases:93.75%
controls:93.23%
cases:91.75%
controls:80.77%
cases:61.86%
controls:40.54%
cases:8.25%
controls:1.24%
cases:62.50%
controls:43.89%
cases:97.87%
controls:82.05%
cases:100.00%
controls:94.77%
90
895
6
65
89
781
8
186
60
392
37
575
8
12
89
955
60
424
36
542
92
786
2
172
83
816
0
45
allopurinol; oral, parenteral
M04AA01 [21604131]
1.9e+00
2.0e+00
—
—
—
1.5e+00
1.6e+00
cases:12.50%
controls:2.08%
cases:10.31%
controls:1.55%
—
—
—
—
—
—
cases:8.51%
controls:2.09%
cases:15.66%
controls:3.48%
12
20
84
940
10
15
87
952
—
—
—
8
20
86
938
13
30
70
831
Reticulocytes/Erythrocytes in Blood
4679-7 [3027945]
—
—
—
—
—
2.8e+00
2.6e+00
—
—
—
—
—
—
—
—
—
—
cases:9.57%
controls:0.63%
cases:13.25%
controls:1.16%
—
—
—
—
—
9
6
85
952
11
10
72
851
Hematology
82 [38004501]
1.9e+00
2.0e+00
—
—
—
2.8e+00
2.6e+00
cases:5.21%
controls:0.83%
cases:5.15%
controls:0.72%
—
—
—
—
—
—
cases:10.64%
controls:0.73%
cases:10.84%
controls:0.93%
5
8
91
952
5
7
92
960
—
—
—
10
7
84
951
9
8
74
853
Reticulocytes [#/volume] in Blood
14196-0 [3023520]
—
—
—
—
—
2.5e+00
2.7e+00
—
—
—
—
—
—
—
—
—
—
cases:7.45%
controls:0.63%
cases:9.64%
controls:0.70%
—
—
—
—
—
7
6
87
952
8
6
75
855
Medical doctor
Z2221 [2001311556]
8.2e-01
1.8e+00
—
1.0e+50
—
1.9e+00
1.5e+00
cases:12.50%
controls:5.94%
cases:12.37%
controls:2.28%
—
—
cases:5.15%
controls:0.00%
—
—
cases:11.70%
controls:1.98%
cases:19.28%
controls:5.23%
12
57
84
903
12
22
85
945
—
5
0
92
967
—
11
19
83
939
16
45
67
816
Diverticular disease of large intestine without perforation or abscess
K57.3 [45567316]
2.1e+00
1.5e+00
—
—
—
3.0e+00
1.4e+00
cases:11.46%
controls:1.56%
cases:5.15%
controls:1.14%
—
—
—
—
—
—
cases:9.57%
controls:0.52%
cases:9.64%
controls:2.44%
11
15
85
945
5
11
92
956
—
—
—
9
5
85
953
8
21
75
840
Cardiology
6 [38004451]
1.0e+00
1.4e+00
—
—
—
1.5e+00
1.1e+00
cases:19.79%
controls:8.13%
cases:13.40%
controls:3.72%
—
—
—
—
—
—
cases:13.83%
controls:3.55%
cases:22.89%
controls:9.06%
19
78
77
882
13
36
84
931
—
—
—
13
34
81
924
19
78
64
783
Lactate dehydrogenase [Enzymatic activity/volume] in Serum or Plasma by Lactate to pyruvate reaction
14804-9 [3022250]
—
—
—
—
—
2.4e+00
2.6e+00
—
—
—
—
—
—
—
—
—
—
cases:6.38%
controls:0.63%
cases:10.84%
controls:0.93%
—
—
—
—
—
6
6
88
952
9
8
74
853
Bilirubin.total [Moles/volume] in Serum or Plasma
14631-6 [3006140]
4.9e-01
1.3e+00
2.4e+00
—
—
1.2e+00
1.2e+00
cases:7.29%
controls:4.58%
cases:11.34%
controls:3.31%
cases:7.22%
controls:0.72%
—
—
—
—
cases:9.57%
controls:3.03%
cases:21.69%
controls:7.43%
7
44
89
916
11
32
86
935
7
7
90
960
—
—
9
29
85
929
18
64
65
797
Essential (primary) hypertension
I10 [45591453]
9.4e-01
1.3e+00
—
1.0e+50
1.8e+00
1.1e+00
1.2e+00
cases:23.96%
controls:10.94%
cases:15.46%
controls:4.96%
—
—
cases:10.31%
controls:0.00%
cases:6.25%
controls:1.04%
cases:15.96%
controls:5.74%
cases:38.55%
controls:16.49%
23
105
73
855
15
48
82
919
—
10
0
87
967
6
10
90
956
15
55
79
903
32
142
51
719
More than one and less than three hours
ZXE10 [2001311401]
1.5e+00
1.2e+00
—
—
—
1.5e+00
1.3e+00
cases:17.71%
controls:4.48%
cases:6.19%
controls:1.86%
—
—
—
—
—
—
cases:9.57%
controls:2.30%
cases:15.66%
controls:4.76%
17
43
79
917
6
18
91
949
—
—
—
9
22
85
936
13
41
70
820
carvedilol; oral
C07AG02 [21601700]
1.6e+00
2.3e+00
—
—
—
2.1e+00
—
cases:6.25%
controls:1.35%
cases:8.25%
controls:0.93%
—
—
—
—
—
—
cases:8.51%
controls:1.15%
—
—
6
13
90
947
8
9
89
958
—
—
—
8
11
86
947
—
Iron/Transferrin [Ratio] in Serum or Plasma
60517-0 [40763571]
—
—
—
—
—
2.2e+00
2.1e+00
—
—
—
—
—
—
—
—
—
—
cases:6.38%
controls:0.73%
cases:9.64%
controls:1.28%
—
—
—
—
—
6
7
88
951
8
11
75
850
Dyspnoea
R06.0 [45558449]
1.9e+00
—
—
—
—
2.4e+00
1.4e+00
cases:10.42%
controls:1.67%
—
—
—
—
—
—
—
—
cases:5.32%
controls:0.52%
cases:10.84%
controls:2.79%
10
16
86
944
—
—
—
—
5
5
89
953
9
24
74
837
Transferrin [Mass/volume] in Serum or Plasma
3034-6 [3004789]
—
—
—
—
—
2.2e+00
2.0e+00
—
—
—
—
—
—
—
—
—
—
cases:6.38%
controls:0.73%
cases:9.64%
controls:1.39%
—
—
—
—
—
6
7
88
951
8
12
75
849
Office Visit
OMOP4822458 [581477]
1.5e+00
7.9e-01
—
—
—
1.5e+00
1.2e+00
cases:26.04%
controls:7.60%
cases:8.25%
controls:3.93%
—
—
—
—
—
—
cases:11.70%
controls:2.82%
cases:22.89%
controls:8.36%
25
73
71
887
8
38
89
929
—
—
—
11
27
83
931
19
72
64
789
Iron [Moles/volume] in Serum or Plasma
14798-3 [3022948]
—
—
—
—
—
2.1e+00
2.0e+00
—
—
—
—
—
—
—
—
—
—
cases:6.38%
controls:0.84%
cases:9.64%
controls:1.39%
—
—
—
—
—
6
8
88
950
8
12
75
849
Upper gastrointestinal surgery
106 [44777669]
6.3e-01
1.3e+00
2.3e+00
1.0e+50
—
9.9e-01
1.3e+00
cases:10.42%
controls:5.83%
cases:7.22%
controls:2.17%
cases:5.15%
controls:0.52%
cases:5.15%
controls:0.00%
—
—
cases:8.51%
controls:3.34%
cases:24.10%
controls:8.01%
10
56
86
904
7
21
90
946
5
5
92
962
5
0
92
967
—
8
32
86
926
20
69
63
792
Casts [#/volume] in Urine by Automated count
51483-6 [3030467]
8.3e-01
8.9e-01
—
—
—
1.9e+00
1.7e+00
cases:6.25%
controls:2.81%
cases:5.15%
controls:2.17%
—
—
—
—
—
—
cases:7.45%
controls:1.15%
cases:15.66%
controls:3.37%
6
27
90
933
5
21
92
946
—
—
—
7
11
87
947
13
29
70
832
Vascular Surgery
77 [38004496]
—
2.1e+00
—
—
—
1.8e+00
1.5e+00
—
—
cases:6.19%
controls:0.83%
—
—
—
—
—
—
cases:6.38%
controls:1.15%
cases:10.84%
controls:2.56%
—
6
8
91
959
—
—
—
6
11
88
947
9
22
74
839
Other gastroenteritis and colitis of infectious and unspecified origin
A09 [45605189]
1.6e+00
—
—
—
—
—
1.8e+00
cases:9.38%
controls:2.08%
—
—
—
—
—
—
—
—
—
—
cases:10.84%
controls:1.97%
9
20
87
940
—
—
—
—
—
9
17
74
844
tramadol; oral, parenteral, rectal
N02AX02 [21604298]
7.2e-01
1.6e+00
—
—
—
1.3e+00
1.7e+00
cases:13.54%
controls:7.08%
cases:13.40%
controls:2.90%
—
—
—
—
—
—
cases:7.45%
controls:2.19%
cases:22.89%
controls:5.11%
13
68
83
892
13
28
84
939
—
—
—
7
21
87
937
19
44
64
817
Gastroenterology
10 [38004455]
1.7e+00
1.4e+00
—
1.0e+50
—
1.7e+00
7.7e-01
cases:14.58%
controls:3.02%
cases:9.28%
controls:2.48%
—
—
cases:8.25%
controls:0.00%
—
—
cases:9.57%
controls:1.98%
cases:10.84%
controls:5.34%
14
29
82
931
9
24
88
943
—
8
0
89
967
—
9
19
85
939
9
46
74
815
One hour or less
ZXE00 [2001311394]
1.2e+00
1.2e+00
—
—
—
2.1e+00
1.1e+00
cases:19.79%
controls:6.77%
cases:7.22%
controls:2.28%
—
—
—
—
—
—
cases:9.57%
controls:1.25%
cases:15.66%
controls:5.81%
19
65
77
895
7
22
90
945
—
—
—
9
12
85
946
13
50
70
811
Obstetrics / Gynecology
16 [38004461]
5.2e-01
1.1e+00
2.2e+00
—
1.6e+00
5.4e-01
3.0e-01
cases:20.83%
controls:13.54%
cases:17.53%
controls:6.72%
cases:9.28%
controls:1.14%
—
—
cases:6.25%
controls:1.35%
cases:10.64%
controls:6.47%
cases:19.28%
controls:14.98%
20
130
76
830
17
65
80
902
9
11
88
956
—
6
13
90
953
10
62
84
896
16
129
67
732
Calcium.ionized [Moles/volume] in Serum or Plasma
1995-0 [3021347]
6.7e-01
9.4e-01
—
—
—
1.8e+00
1.4e+00
cases:7.29%
controls:3.85%
cases:5.15%
controls:2.07%
—
—
—
—
—
—
cases:8.51%
controls:1.46%
cases:19.28%
controls:5.46%
7
37
89
923
5
20
92
947
—
—
—
8
14
86
944
16
47
67
814
Scheduled procedure
ZXD10 [2001311387]
1.3e+00
1.3e+00
—
—
—
1.9e+00
9.7e-01
cases:21.88%
controls:7.29%
cases:8.25%
controls:2.28%
—
—
—
—
—
—
cases:10.64%
controls:1.67%
cases:13.25%
controls:5.46%
21
70
75
890
8
22
89
945
—
—
—
10
16
84
942
11
47
72
814
calcium carbonate
A02AC01 [21600065]
—
—
—
—
—
—
3.1e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:13.25%
controls:0.70%
—
—
—
—
—
—
11
6
72
855
calcium carbonate; oral
A12AA04 [21600863]
—
—
—
—
—
—
3.1e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:13.25%
controls:0.70%
—
—
—
—
—
—
11
6
72
855
Abdominal ultrasound examination
JN3AE [2001305555]
1.6e+00
—
—
—
—
—
3.0e+00
cases:5.21%
controls:1.04%
—
—
—
—
—
—
—
—
—
—
cases:14.46%
controls:0.81%
5
10
91
950
—
—
—
—
—
12
7
71
854
Differential panel, method unspecified - Blood
69738-3 [42870588]
6.6e-01
1.2e+00
—
—
—
1.7e+00
1.3e+00
cases:6.25%
controls:3.33%
cases:7.22%
controls:2.28%
—
—
—
—
—
—
cases:9.57%
controls:1.88%
cases:14.46%
controls:4.41%
6
32
90
928
7
22
90
945
—
—
—
9
18
85
940
12
38
71
823
Chronic kidney disease, unspecified
N18.9 [45553438]
—
—
—
—
—
—
2.8e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:12.05%
controls:0.81%
—
—
—
—
—
—
10
7
73
854
Ultrasound examination of upper part of abdomen
JN1AE [2001305517]
—
—
—
—
—
—
2.8e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:8.43%
controls:0.58%
—
—
—
—
—
—
7
5
76
856
Other extensive ultrasound examination of artery
PG1DE [2001309713]
—
—
—
—
—
1.0e+50
2.8e+00
—
—
—
—
—
—
—
—
—
—
cases:5.32%
controls:0.00%
cases:8.43%
controls:0.58%
—
—
—
—
—
5
0
89
958
7
5
76
856
Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (MDRD)/1.73 sq M
77147-7 [46236952]
—
—
—
—
—
—
2.7e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:10.84%
controls:0.81%
—
—
—
—
—
—
9
7
74
854
General Practice Dentistry
1223G0001X [38003675]
—
—
—
—
—
—
2.7e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:12.05%
controls:0.93%
—
—
—
—
—
—
10
8
73
853
esomeprazole; oral, parenteral
A02BC05 [21600100]
6.6e-01
1.4e+00
1.5e+00
—
—
7.8e-01
1.3e+00
cases:14.58%
controls:8.13%
cases:12.37%
controls:3.52%
cases:5.15%
controls:1.14%
—
—
—
—
cases:8.51%
controls:4.07%
cases:21.69%
controls:7.32%
14
78
82
882
12
34
85
933
5
11
92
956
—
—
8
39
86
919
18
63
65
798
Insertion of central venous catheter through external or internal jugular vein
TPH15 [2001309600]
—
—
—
—
—
—
2.6e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:7.23%
controls:0.58%
—
—
—
—
—
—
6
5
77
856
Right side
ZXA00 [2001311346]
—
—
—
—
—
2.6e+00
1.3e+00
—
—
—
—
—
—
—
—
—
—
cases:6.38%
controls:0.52%
cases:13.25%
controls:3.95%
—
—
—
—
—
6
5
88
953
11
34
72
827
Parathyrin.intact [Mass/volume] in Serum or Plasma
2731-8 [3000067]
-1.0e+50
—
—
—
—
—
2.6e+00
cases:0.00%
controls:0.73%
—
—
—
—
—
—
—
—
—
—
cases:12.05%
controls:1.05%
0
7
96
953
—
—
—
—
—
10
9
73
852
Handing over of treatment supplies
SPAT1262 [2001700363]
1.4e+00
1.9e+00
—
—
—
2.5e+00
7.6e-01
cases:5.21%
controls:1.35%
cases:5.15%
controls:0.83%
—
—
—
—
—
—
cases:8.51%
controls:0.73%
cases:9.64%
controls:4.76%
5
13
91
947
5
8
92
959
—
—
—
8
7
86
951
8
41
75
820
Chronic kidney disease
N18 [45582391]
2.5e+00
—
—
—
—
—
—
cases:8.33%
controls:0.73%
—
—
—
—
—
—
—
—
—
—
—
—
8
7
88
953
—
—
—
—
—
—
Neutrophils [#/volume] in Blood by Automated count
751-8 [3013650]
3.7e-01
9.4e-01
2.5e+00
—
—
1.0e+00
8.7e-01
cases:9.38%
controls:6.67%
cases:9.28%
controls:3.83%
cases:8.25%
controls:0.72%
—
—
—
—
cases:11.70%
controls:4.49%
cases:19.28%
controls:9.06%
9
64
87
896
9
37
88
930
8
7
89
960
—
—
11
43
83
915
16
78
67
783
Case Management Agency
251B00000X [38004193]
4.7e-01
4.4e-01
8.0e-01
2.5e+00
5.5e-01
4.1e-01
5.2e-01
cases:59.38%
controls:47.71%
cases:51.55%
controls:40.64%
cases:28.87%
controls:15.41%
cases:13.40%
controls:1.24%
cases:23.96%
controls:15.32%
cases:55.32%
controls:44.99%
cases:80.72%
controls:71.31%
57
458
39
502
50
393
47
574
28
149
69
818
13
12
84
955
23
148
73
818
52
431
42
527
67
614
16
247
Fever, unspecified
R50.9 [45582716]
2.5e+00
—
—
—
—
—
—
cases:9.38%
controls:0.83%
—
—
—
—
—
—
—
—
—
—
—
—
9
8
87
952
—
—
—
—
—
—
losartan and diuretics
C09DA01 [21601834]
2.5e+00
—
—
—
—
—
—
cases:9.38%
controls:0.83%
—
—
—
—
—
—
—
—
—
—
—
—
9
8
87
952
—
—
—
—
—
—
Infectious Disease
44 [38004484]
1.7e+00
—
—
—
—
1.9e+00
2.4e+00
cases:7.29%
controls:1.35%
—
—
—
—
—
—
—
—
cases:5.32%
controls:0.84%
cases:10.84%
controls:1.05%
7
13
89
947
—
—
—
—
5
8
89
950
9
9
74
852
sulfamethoxazole and trimethoprim
J01EE01 [21602961]
—
—
—
—
—
—
2.4e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:8.43%
controls:0.81%
—
—
—
—
—
—
7
7
76
854
colecalciferol; oral
A11CC05 [21600820]
—
—
—
—
—
—
2.4e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:6.02%
controls:0.58%
—
—
—
—
—
—
5
5
78
856
moxifloxacin; oral, parenteral
J01MA14 [21603021]
—
—
—
—
—
—
2.4e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:6.02%
controls:0.58%
—
—
—
—
—
—
5
5
78
856
amlodipine; oral
C08CA01 [21601747]
9.3e-01
1.0e+00
—
—
—
9.3e-01
1.4e+00
cases:19.79%
controls:8.85%
cases:16.49%
controls:6.62%
—
—
—
—
—
—
cases:17.02%
controls:7.52%
cases:32.53%
controls:11.03%
19
85
77
875
16
64
81
903
—
—
—
16
72
78
886
27
95
56
766
Nonallergic asthma
J45.1 [45557625]
—
—
—
—
—
2.4e+00
—
—
—
—
—
—
—
—
—
—
—
cases:5.32%
controls:0.52%
—
—
—
—
—
—
—
5
5
89
953
—
calcium (different salts in combination); oral
A12AA20 [21600872]
5.9e-01
6.7e-01
—
—
-1.0e+50
1.2e+00
1.2e+00
cases:13.54%
controls:8.02%
cases:12.37%
controls:6.72%
—
—
—
—
cases:0.00%
controls:1.35%
cases:18.09%
controls:6.37%
cases:25.30%
controls:9.41%
13
77
83
883
12
65
85
902
—
—
0
13
96
953
17
61
77
897
21
81
62
780
Ultrasound examination of pregnancy (at 12. week of gestaion or later) including basic examination of fetus
MA2AE [2001306829]
—
2.4e+00
—
—
—
—
7.6e-01
—
—
cases:6.19%
controls:0.62%
—
—
—
—
—
—
—
—
cases:6.02%
controls:2.90%
—
6
6
91
961
—
—
—
—
5
25
78
836
Bacterial pneumonia, unspecified
J15.9 [45557621]
2.3e+00
—
—
—
—
—
—
cases:5.21%
controls:0.52%
—
—
—
—
—
—
—
—
—
—
—
—
5
5
91
955
—
—
—
—
—
—
Unspecified haematuria
R31 [45553726]
2.3e+00
—
—
—
—
—
—
cases:5.21%
controls:0.52%
—
—
—
—
—
—
—
—
—
—
—
—
5
5
91
955
—
—
—
—
—
—
Other specified special examinations
Z01.8 [45581003]
—
2.3e+00
—
—
—
—
—
—
—
cases:5.15%
controls:0.52%
—
—
—
—
—
—
—
—
—
—
—
5
5
92
962
—
—
—
—
—
Phosphate [Moles/volume] in Serum or Plasma
14879-1 [3003458]
—
—
—
—
—
—
2.3e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:15.66%
controls:1.86%
—
—
—
—
—
—
13
16
70
845
Biopsy of skin and subcutaneous tissue
TQX10 [2001310152]
—
—
—
—
—
—
2.2e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:7.23%
controls:0.81%
—
—
—
—
—
—
6
7
77
854
Bilateral
ZXA10 [2001311348]
2.2e+00
-1.0e+50
—
—
—
—
—
cases:8.33%
controls:1.04%
cases:0.00%
controls:0.72%
—
—
—
—
—
—
—
—
—
—
8
10
88
950
0
7
97
960
—
—
—
—
—
Standard cardiac ultrasound examination
FM1AE [2001303278]
—
2.1e+00
—
—
—
—
1.4e+00
—
—
cases:8.25%
controls:1.03%
—
—
—
—
—
—
—
—
cases:10.84%
controls:2.79%
—
8
10
89
957
—
—
—
—
9
24
74
837
Hepatitis C virus Ab [Presence] in Serum
16128-1 [3017143]
1.8e+00
—
—
—
—
—
2.1e+00
cases:6.25%
controls:1.04%
—
—
—
—
—
—
—
—
—
—
cases:10.84%
controls:1.39%
6
10
90
950
—
—
—
—
—
9
12
74
849
Lumbar spine X-ray examination without contrast
NA3AA [2001307026]
-1.0e+50
—
—
—
—
—
2.1e+00
cases:0.00%
controls:0.73%
—
—
—
—
—
—
—
—
—
—
cases:10.84%
controls:1.39%
0
7
96
953
—
—
—
—
—
9
12
74
849
Erythrocyte [DistWidth] in Red Blood Cells
30385-9 [3002385]
1.1e-01
5.2e-01
2.1e+00
—
7.7e-01
3.4e-01
4.6e-01
cases:14.58%
controls:13.23%
cases:17.53%
controls:11.17%
cases:12.37%
controls:1.65%
—
—
cases:5.21%
controls:2.48%
cases:17.02%
controls:12.73%
cases:34.94%
controls:25.32%
14
127
82
833
17
108
80
859
12
16
85
951
—
5
24
91
942
16
122
78
836
29
218
54
643
Thorax X-ray examination outside radiological department
GD1UA [2001303652]
2.1e+00
—
—
—
—
—
—
cases:7.29%
controls:0.94%
—
—
—
—
—
—
—
—
—
—
—
—
7
9
89
951
—
—
—
—
—
—
C reactive protein [Mass/volume] in Serum or Plasma
1988-5 [3020460]
-2.3e-01
5.9e-01
2.1e+00
—
1.4e+00
6.8e-01
5.1e-01
cases:13.54%
controls:16.46%
cases:17.53%
controls:10.55%
cases:9.28%
controls:1.24%
—
—
cases:7.29%
controls:1.86%
cases:20.21%
controls:11.38%
cases:38.55%
controls:27.29%
13
158
83
802
17
102
80
865
9
12
88
955
—
7
18
89
948
19
109
75
849
32
235
51
626
Magnesium [Moles/volume] in Serum or Plasma
2601-3 [3012095]
—
—
—
—
—
—
2.1e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:8.43%
controls:1.16%
—
—
—
—
—
—
7
10
76
851
Social worker
Z2446 [2001311559]
—
—
—
—
—
—
2.1e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:8.43%
controls:1.16%
—
—
—
—
—
—
7
10
76
851
Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma
6768-6 [3035995]
-1.4e-01
6.6e-01
2.0e+00
—
—
8.4e-01
8.6e-01
cases:7.29%
controls:8.33%
cases:10.31%
controls:5.58%
cases:7.22%
controls:1.03%
—
—
—
—
cases:12.77%
controls:5.95%
cases:27.71%
controls:13.94%
7
80
89
880
10
54
87
913
7
10
90
957
—
—
12
57
82
901
23
120
60
741
cefalexin; oral
J01DB01 [21602870]
7.9e-01
6.8e-01
1.8e+00
—
—
1.2e+00
6.7e-01
cases:45.83%
controls:27.81%
cases:16.49%
controls:9.10%
cases:6.19%
controls:1.03%
—
—
—
—
cases:23.40%
controls:8.56%
cases:43.37%
controls:28.22%
44
267
52
693
16
88
81
879
6
10
91
957
—
—
22
82
72
876
36
243
47
618
Sodium [Moles/volume] in Serum or Plasma
2951-2 [3019550]
-1.3e-01
3.5e-01
1.9e+00
—
1.5e+00
4.9e-01
3.9e-01
cases:13.54%
controls:15.10%
cases:14.43%
controls:10.65%
cases:9.28%
controls:1.45%
—
—
cases:7.29%
controls:1.76%
cases:19.15%
controls:12.63%
cases:39.76%
controls:30.89%
13
145
83
815
14
103
83
864
9
14
88
953
—
7
17
89
949
18
121
76
837
33
266
50
595
Potassium [Moles/volume] in Serum or Plasma
2823-3 [3023103]
-1.3e-01
4.1e-01
1.9e+00
—
1.5e+00
4.7e-01
4.5e-01
cases:13.54%
controls:15.10%
cases:15.46%
controls:10.86%
cases:9.28%
controls:1.45%
—
—
cases:7.29%
controls:1.76%
cases:19.15%
controls:12.84%
cases:40.96%
controls:30.78%
13
145
83
815
15
105
82
862
9
14
88
953
—
7
17
89
949
18
123
76
835
34
265
49
596
Leukocytes [#/volume] in Blood
26464-8 [3010813]
-2.0e-02
4.6e-01
1.9e+00
—
1.1e+00
3.7e-01
2.4e-01
cases:19.79%
controls:20.10%
cases:23.71%
controls:16.44%
cases:15.46%
controls:2.59%
—
—
cases:9.38%
controls:3.42%
cases:25.53%
controls:19.21%
cases:44.58%
controls:38.68%
19
193
77
767
23
159
74
808
15
25
82
942
—
9
33
87
933
24
184
70
774
37
333
46
528
clopidogrel; oral
B01AC04 [21600989]
7.2e-01
1.5e+00
—
—
—
1.6e+00
1.9e+00
cases:5.21%
controls:2.60%
cases:5.15%
controls:1.24%
—
—
—
—
—
—
cases:5.32%
controls:1.15%
cases:12.05%
controls:1.97%
5
25
91
935
5
12
92
955
—
—
—
5
11
89
947
10
17
73
844
lercanidipine; oral
C08CA13 [21601759]
—
—
—
—
—
1.5e+00
1.9e+00
—
—
—
—
—
—
—
—
—
—
cases:6.38%
controls:1.46%
cases:12.05%
controls:1.97%
—
—
—
—
—
6
14
88
944
10
17
73
844
Epithelial cells [#/volume] in Urine
30383-4 [3000850]
8.5e-01
—
—
—
—
—
1.9e+00
cases:5.21%
controls:2.29%
—
—
—
—
—
—
—
—
—
—
cases:13.25%
controls:2.21%
5
22
91
938
—
—
—
—
—
11
19
72
842
Platelets [#/volume] in Blood
26515-7 [3007461]
-6.5e-03
4.6e-01
1.9e+00
—
1.0e+00
3.7e-01
2.5e-01
cases:19.79%
controls:19.90%
cases:23.71%
controls:16.34%
cases:15.46%
controls:2.69%
—
—
cases:9.38%
controls:3.52%
cases:25.53%
controls:19.21%
cases:44.58%
controls:38.56%
19
191
77
769
23
158
74
809
15
26
82
941
—
9
34
87
932
24
184
70
774
37
332
46
529
Hemoglobin [Mass/volume] in Blood
718-7 [3000963]
-1.3e-02
4.6e-01
1.9e+00
—
1.0e+00
3.6e-01
2.4e-01
cases:19.79%
controls:20.00%
cases:23.71%
controls:16.34%
cases:15.46%
controls:2.69%
—
—
cases:9.38%
controls:3.62%
cases:25.53%
controls:19.31%
cases:44.58%
controls:38.68%
19
192
77
768
23
158
74
809
15
26
82
941
—
9
35
87
931
24
185
70
773
37
333
46
528
Erythrocytes [#/volume] in Blood
26453-1 [3026361]
-1.3e-02
4.6e-01
1.9e+00
—
1.0e+00
3.6e-01
2.4e-01
cases:19.79%
controls:20.00%
cases:23.71%
controls:16.34%
cases:15.46%
controls:2.69%
—
—
cases:9.38%
controls:3.62%
cases:25.53%
controls:19.31%
cases:44.58%
controls:38.68%
19
192
77
768
23
158
74
809
15
26
82
941
—
9
35
87
931
24
185
70
773
37
333
46
528
MCH [Entitic mass]
28539-5 [3035941]
-1.3e-02
4.6e-01
1.9e+00
—
1.0e+00
3.6e-01
2.4e-01
cases:19.79%
controls:20.00%
cases:23.71%
controls:16.34%
cases:15.46%
controls:2.69%
—
—
cases:9.38%
controls:3.62%
cases:25.53%
controls:19.31%
cases:44.58%
controls:38.68%
19
192
77
768
23
158
74
809
15
26
82
941
—
9
35
87
931
24
185
70
773
37
333
46
528
Hematocrit [Volume Fraction] of Blood by calculation
20570-8 [3009542]
-1.3e-02
4.6e-01
1.9e+00
—
1.0e+00
3.6e-01
2.4e-01
cases:19.79%
controls:20.00%
cases:23.71%
controls:16.34%
cases:15.46%
controls:2.69%
—
—
cases:9.38%
controls:3.62%
cases:25.53%
controls:19.31%
cases:44.58%
controls:38.68%
19
192
77
768
23
158
74
809
15
26
82
941
—
9
35
87
931
24
185
70
773
37
333
46
528
MCV [Entitic mean volume] in Red Blood Cells
30428-7 [3024731]
-1.3e-02
4.6e-01
1.9e+00
—
1.0e+00
3.6e-01
2.4e-01
cases:19.79%
controls:20.00%
cases:23.71%
controls:16.34%
cases:15.46%
controls:2.69%
—
—
cases:9.38%
controls:3.62%
cases:25.53%
controls:19.31%
cases:44.58%
controls:38.68%
19
192
77
768
23
158
74
809
15
26
82
941
—
9
35
87
931
24
185
70
773
37
333
46
528
Cathetrisation of vein
TPH04 [2001309597]
1.1e+00
—
—
—
—
—
1.9e+00
cases:7.29%
controls:2.50%
—
—
—
—
—
—
—
—
—
—
cases:12.05%
controls:2.09%
7
24
89
936
—
—
—
—
—
10
18
73
843
alendronic acid; oral
M05BA04 [21604152]
1.8e+00
—
—
—
—
—
1.6e+00
cases:7.29%
controls:1.25%
—
—
—
—
—
—
—
—
—
—
cases:7.23%
controls:1.51%
7
12
89
948
—
—
—
—
—
6
13
77
848
Creatinine [Moles/volume] in Serum or Plasma
14682-9 [3020564]
-6.9e-02
4.8e-01
1.8e+00
—
1.4e+00
3.3e-01
2.9e-01
cases:15.63%
controls:16.56%
cases:18.56%
controls:12.31%
cases:10.31%
controls:1.86%
—
—
cases:8.33%
controls:2.28%
cases:20.21%
controls:15.34%
cases:40.96%
controls:34.26%
15
159
81
801
18
119
79
848
10
18
87
949
—
8
22
88
944
19
147
75
811
34
295
49
566
Bacteria [Presence] in Urine
87829-8 [36304419]
6.8e-01
—
—
—
—
1.8e+00
1.7e+00
cases:5.21%
controls:2.71%
—
—
—
—
—
—
—
—
cases:6.38%
controls:1.15%
cases:15.66%
controls:3.14%
5
26
91
934
—
—
—
—
6
11
88
947
13
27
70
834
Urinalysis microscopic panel [#/volume] - Urine by Automated count
50554-5 [3029287]
5.1e-01
—
—
—
—
1.7e+00
1.7e+00
cases:6.25%
controls:3.85%
—
—
—
—
—
—
—
—
cases:7.45%
controls:1.46%
cases:19.28%
controls:4.07%
6
37
90
923
—
—
—
—
7
14
87
944
16
35
67
826
hydrochlorothiazide; oral
C03AA03 [21601466]
1.7e+00
—
—
—
—
—
—
cases:8.33%
controls:1.67%
—
—
—
—
—
—
—
—
—
—
—
—
8
16
88
944
—
—
—
—
—
—
Prothrombin time (PT) actual/Normal
5894-1 [3033658]
—
1.1e+00
—
—
—
2.2e+00
1.6e+00
—
—
cases:5.15%
controls:1.86%
—
—
—
—
—
—
cases:5.32%
controls:0.63%
cases:18.07%
controls:4.07%
—
5
18
92
949
—
—
—
5
6
89
952
15
35
68
826
Osmolality of Urine
2695-5 [3026782]
9.0e-01
—
—
—
—
—
1.6e+00
cases:5.21%
controls:2.19%
—
—
—
—
—
—
—
—
—
—
cases:12.05%
controls:2.67%
5
21
91
939
—
—
—
—
—
10
23
73
838
MCHC [Entitic Mass/volume] in Red Blood Cells
28540-3 [3003338]
-2.4e-02
3.9e-01
1.6e+00
—
6.9e-01
2.1e-01
2.9e-01
cases:15.63%
controls:15.94%
cases:17.53%
controls:12.62%
cases:10.31%
controls:2.28%
—
—
cases:5.21%
controls:2.69%
cases:17.02%
controls:14.30%
cases:37.35%
controls:30.89%
15
153
81
807
17
122
80
845
10
22
87
945
—
5
26
91
940
16
137
78
821
31
266
52
595
temazepam; oral
N05CD07 [21604642]
—
—
—
—
—
—
1.6e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:12.05%
controls:2.79%
—
—
—
—
—
—
10
24
73
837
Erythrocytes [#/volume] in Urine
30391-7 [3002582]
6.3e-01
8.0e-01
—
—
—
1.6e+00
1.5e+00
cases:6.25%
controls:3.44%
cases:5.15%
controls:2.38%
—
—
—
—
—
—
cases:7.45%
controls:1.57%
cases:16.87%
controls:4.30%
6
33
90
927
5
23
92
944
—
—
—
7
15
87
943
14
37
69
824
Hepatitis B virus surface Ag [Presence] in Serum
5195-3 [3019284]
5.7e-01
—
—
—
—
—
1.5e+00
cases:5.21%
controls:3.02%
—
—
—
—
—
—
—
—
—
—
cases:18.07%
controls:4.76%
5
29
91
931
—
—
—
—
—
15
41
68
820
pH of Serum or Plasma
2753-2 [3018418]
7.6e-01
1.4e+00
—
—
—
1.6e+00
1.5e+00
cases:5.21%
controls:2.50%
cases:5.15%
controls:1.34%
—
—
—
—
—
—
cases:5.32%
controls:1.15%
cases:13.25%
controls:3.37%
5
24
91
936
5
13
92
954
—
—
—
5
11
89
947
11
29
72
832
Urgent procedure
ZXD05 [2001311386]
9.8e-01
—
—
—
—
1.6e+00
1.4e+00
cases:10.42%
controls:4.17%
—
—
—
—
—
—
—
—
cases:6.38%
controls:1.36%
cases:15.66%
controls:4.18%
10
40
86
920
—
—
—
—
6
13
88
945
13
36
70
825
Albumin [Mass/volume] in Urine
1754-1 [3012516]
—
—
—
—
—
—
1.4e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:19.28%
controls:5.34%
—
—
—
—
—
—
16
46
67
815
Chest pain, unspecified
R07.4 [45558450]
8.2e-01
—
—
—
—
—
1.4e+00
cases:8.33%
controls:3.85%
—
—
—
—
—
—
—
—
—
—
cases:14.46%
controls:3.95%
8
37
88
923
—
—
—
—
—
12
34
71
827
Periodontal treatment by dental hygienist, extensive
SDE03 [2001310351]
—
—
—
—
—
-1.0e+50
1.4e+00
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.52%
cases:12.05%
controls:3.25%
—
—
—
—
—
0
5
94
953
10
28
73
833
HIV 1 and 2 tests - Meaningful Use set
75622-1 [46235355]
—
—
—
—
—
1.4e+00
1.4e+00
—
—
—
—
—
—
—
—
—
—
cases:5.32%
controls:1.36%
cases:18.07%
controls:5.23%
—
—
—
—
—
5
13
89
945
15
45
68
816
Ferritin [Mass/volume] in Serum or Plasma
2276-4 [3001122]
6.9e-01
1.2e+00
—
—
—
1.4e+00
7.2e-01
cases:8.33%
controls:4.38%
cases:9.28%
controls:3.00%
—
—
—
—
—
—
cases:12.77%
controls:3.55%
cases:19.28%
controls:10.45%
8
42
88
918
9
29
88
938
—
—
—
12
34
82
924
16
90
67
771
Laboratory Visit
OMOP4822461 [32036]
-1.0e-01
4.8e-02
1.4e+00
—
8.3e-01
2.9e-01
2.4e-01
cases:20.83%
controls:22.60%
cases:23.71%
controls:22.85%
cases:20.62%
controls:6.31%
—
—
cases:15.63%
controls:7.45%
cases:29.79%
controls:24.01%
cases:48.19%
controls:42.16%
20
217
76
743
23
221
74
746
20
61
77
906
—
15
72
81
894
28
230
66
728
40
363
43
498
Albumin [Mass/volume] in Serum or Plasma
1751-7 [3024561]
7.3e-01
1.3e+00
—
—
—
1.1e+00
1.3e+00
cases:6.25%
controls:3.13%
cases:7.22%
controls:2.17%
—
—
—
—
—
—
cases:6.38%
controls:2.30%
cases:21.69%
controls:6.74%
6
30
90
930
7
21
90
946
—
—
—
6
22
88
936
18
58
65
803
ciprofloxacin; oral, parenteral
J01MA02 [21603009]
5.5e-02
1.4e+00
—
—
—
1.3e+00
1.3e+00
cases:6.25%
controls:5.94%
cases:7.22%
controls:1.96%
—
—
—
—
—
—
cases:5.32%
controls:1.46%
cases:16.87%
controls:5.11%
6
57
90
903
7
19
90
948
—
—
—
5
14
89
944
14
44
69
817
Leukocytes [#/volume] in Urine
30405-5 [3018095]
4.5e-01
9.1e-01
—
—
—
1.6e+00
1.3e+00
cases:6.25%
controls:4.06%
cases:6.19%
controls:2.59%
—
—
—
—
—
—
cases:7.45%
controls:1.67%
cases:16.87%
controls:5.23%
6
39
90
921
6
25
91
942
—
—
—
7
16
87
942
14
45
69
816
Counselling related to known health issue
SPAT1310 [2001700411]
5.7e-01
—
—
—
—
—
1.3e+00
cases:6.25%
controls:3.65%
—
—
—
—
—
—
—
—
—
—
cases:18.07%
controls:5.69%
6
35
90
925
—
—
—
—
—
15
49
68
812
Calcium.ionized [Moles/volume] adjusted to pH 7.4 in Serum or Plasma
19072-8 [3016431]
5.7e-01
1.0e+00
—
—
—
1.5e+00
1.3e+00
cases:7.29%
controls:4.27%
cases:6.19%
controls:2.28%
—
—
—
—
—
—
cases:8.51%
controls:2.09%
cases:21.69%
controls:7.08%
7
41
89
919
6
22
91
945
—
—
—
8
20
86
938
18
61
65
800
Pulmonary Disease
29 [38004472]
1.2e+00
1.2e+00
—
—
-1.0e+50
1.3e+00
9.1e-01
cases:15.63%
controls:5.42%
cases:11.34%
controls:3.62%
—
—
—
—
cases:0.00%
controls:0.83%
cases:10.64%
controls:3.13%
cases:15.66%
controls:6.97%
15
52
81
908
11
35
86
932
—
—
0
8
96
958
10
30
84
928
13
60
70
801
Creatinine [Moles/volume] in Urine
14683-7 [3009508]
—
—
—
—
—
—
1.2e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:18.07%
controls:6.39%
—
—
—
—
—
—
15
55
68
806
Albumin/Creatinine [Ratio] in Urine
32294-1 [3020682]
—
—
—
—
—
—
1.2e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:18.07%
controls:6.39%
—
—
—
—
—
—
15
55
68
806
Physical Medicine And Rehabilitation
25 [38004468]
1.1e+00
—
—
—
—
—
9.5e-01
cases:13.54%
controls:4.79%
—
—
—
—
—
—
—
—
—
—
cases:13.25%
controls:5.57%
13
46
83
914
—
—
—
—
—
11
48
72
813
amoxicillin; oral, parenteral
J01CA04 [21602823]
4.2e-01
1.0e+00
—
—
—
1.1e+00
7.5e-01
cases:29.17%
controls:21.35%
cases:14.43%
controls:5.58%
—
—
—
—
—
—
cases:15.96%
controls:5.85%
cases:36.14%
controls:21.14%
28
205
68
755
14
54
83
913
—
—
—
15
56
79
902
30
182
53
679
General Practice
1 [38004446]
1.2e-01
1.1e+00
—
1.0e+50
2.0e+00
8.4e-01
-2.1e-01
cases:12.50%
controls:11.25%
cases:14.43%
controls:5.38%
—
—
cases:7.22%
controls:0.00%
cases:6.25%
controls:0.93%
cases:8.51%
controls:3.86%
cases:13.25%
controls:15.91%
12
108
84
852
14
52
83
915
—
7
0
90
967
6
9
90
957
8
37
86
921
11
137
72
724
Clinical & Laboratory Dermatological Immunology Physician
207NI0002X [38003841]
5.9e-01
9.1e-01
—
—
—
1.2e+00
1.1e+00
cases:10.42%
controls:6.04%
cases:6.19%
controls:2.59%
—
—
—
—
—
—
cases:8.51%
controls:2.61%
cases:20.48%
controls:8.13%
10
58
86
902
6
25
91
942
—
—
—
8
25
86
933
17
70
66
791
pantoprazole; oral, parenteral
A02BC02 [21600097]
4.1e-01
1.1e+00
—
—
—
8.1e-01
5.9e-01
cases:17.71%
controls:12.50%
cases:17.53%
controls:6.83%
—
—
—
—
—
—
cases:13.83%
controls:6.68%
cases:27.71%
controls:17.54%
17
120
79
840
17
66
80
901
—
—
—
13
64
81
894
23
151
60
710
General Surgery
2 [38004447]
5.7e-01
7.6e-01
—
1.0e+50
—
9.4e-01
9.7e-01
cases:31.25%
controls:20.42%
cases:13.40%
controls:6.72%
—
—
cases:5.15%
controls:0.00%
—
—
cases:18.09%
controls:7.93%
cases:33.73%
controls:16.14%
30
196
66
764
13
65
84
902
—
5
0
92
967
—
17
76
77
882
28
139
55
722
Postpartum check-up
SPAT1380 [2001700480]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:0.83%
—
—
—
—
—
—
—
—
—
—
—
0
8
97
959
—
—
—
—
—
Rheumatoid/seropositive arthritis
L88 [2002000707]
-1.0e+50
—
—
—
—
—
-1.0e+50
cases:0.00%
controls:0.52%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.58%
0
5
96
955
—
—
—
—
—
0
5
83
856
Observ/health educat/advice/diet
-45 [2002000116]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.58%
—
—
—
—
—
—
0
5
83
856
Methemoglobin/Hemoglobin.total in Arterial blood
2615-3 [3006217]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.70%
—
—
—
—
—
—
0
6
83
855
Mouth/tongue/lip symptom/complaint
D20 [2002000319]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.58%
—
—
—
—
—
—
0
5
83
856
Dulaglutide, exenatide, liraglutide, lixisenatide and semaglutide (adults)
346 [2001600307]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.58%
—
—
—
—
—
—
0
5
83
856
Ear pain/earache
H01 [2002000475]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.51%
—
—
—
—
—
—
0
13
83
848
MCM6 gene c.-13910C>T and -13915T>G [Identifier] in Blood or Tissue by Molecular genetics method Nominal
72872-5 [43534045]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.58%
—
—
—
—
—
—
0
5
83
856
Melanocytic naevi, unspecified
D22.9 [45571603]
-1.0e+50
—
—
—
—
—
-1.0e+50
cases:0.00%
controls:0.63%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.81%
0
6
96
954
—
—
—
—
—
0
7
83
854
Hypertension uncomplicated
K86 [2002000613]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:1.04%
—
—
—
—
—
—
—
—
—
—
—
—
0
10
96
950
—
—
—
—
—
—
Morphology ultrasound screening, weeks 18+0 to 21+6 of gestation
MA5AE [2001306841]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.63%
—
—
—
—
—
—
—
—
—
—
—
—
0
6
96
954
—
—
—
—
—
—
Sick sinus syndrome
I49.5 [45562354]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.58%
—
—
—
—
—
—
0
5
83
856
ketoprofen; ointment
M02AA10 [21604046]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.52%
—
—
—
—
—
—
—
0
5
94
953
—
Ultrasound examination of paranasal sinuses
SPAT1028 [2001700129]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.81%
—
—
—
—
—
—
0
7
83
854
Skin Pathology biopsy report
65754-4 [40768443]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.81%
—
—
—
—
—
—
0
7
83
854
isosorbide mononitrate; oral
C01DA14 [21600324]
5.9e-01
7.2e-01
-1.0e+50
—
—
7.5e-01
9.0e-01
cases:7.29%
controls:4.17%
cases:6.19%
controls:3.10%
cases:0.00%
controls:0.93%
—
—
—
—
cases:6.38%
controls:3.13%
cases:8.43%
controls:3.60%
7
40
89
920
6
30
91
937
0
9
97
958
—
—
6
30
88
928
7
31
76
830
Primary degenerative dementia of the Alzheimer's type, senile onset without additional symptoms
F00.10*G30.1 [2000501573]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.73%
—
—
—
—
—
—
—
0
7
94
951
—
Fetal Nuchal fold [Multiple of the median] Thickness adjusted for maternal weight
60477-7 [40763531]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:1.25%
—
—
—
—
—
—
—
—
—
—
—
—
0
12
96
948
—
—
—
—
—
—
Holo-transcobalamin II [Moles/volume] in Serum
72160-5 [43054903]
—
—
—
—
—
1.5e+00
8.4e-01
—
—
—
—
—
—
—
—
—
—
cases:6.38%
controls:1.46%
cases:15.66%
controls:7.43%
—
—
—
—
—
6
14
88
944
13
64
70
797
Opening and preparing the root canals, extremely complicated And time consuming
SGA05 [2001310383]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.58%
—
—
—
—
—
—
0
5
83
856
Naevus/mole
S82 [2002001046]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.83%
—
—
—
—
—
—
—
—
—
—
—
—
0
8
96
952
—
—
—
—
—
—
Fetal Trisomy 21 risk [Likelihood] Based on maternal age
49090-4 [3049207]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:1.25%
—
—
—
—
—
—
—
—
—
—
—
—
0
12
96
948
—
—
—
—
—
—
Impingement syndrome of shoulder
M75.4 [45553266]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.63%
—
—
—
—
—
—
—
—
—
—
—
—
0
6
96
954
—
—
—
—
—
—
Extensive health check-up at 18 months of age
SPAT1382 [2001700482]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.73%
—
—
—
—
—
—
—
—
—
—
—
—
0
7
96
953
—
—
—
—
—
—
Demanding operative extraction of tooth
EBA12 [2001301926]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.70%
—
—
—
—
—
—
0
6
83
855
Migraine, unspecified
G43.9 [45595943]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.94%
—
—
—
—
—
—
—
—
—
—
—
—
0
9
96
951
—
—
—
—
—
—
Asthma, unspecified
J45.9 [45562456]
—
—
—
—
—
—
1.2e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:9.64%
controls:3.02%
—
—
—
—
—
—
8
26
75
835
Bacteria [#/volume] in Urine by Culture
100906-7 [1761482]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.05%
—
—
—
—
—
—
0
9
83
852
Ganglion
M67.4 [45582222]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.81%
—
—
—
—
—
—
0
7
83
854
Myopia
H52.1 [45533352]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.81%
—
—
—
—
—
—
0
7
83
854
bisoprolol; oral
C07AB07 [21601689]
5.5e-01
7.1e-01
—
—
1.2e+00
8.4e-01
7.0e-01
cases:21.88%
controls:13.96%
cases:21.65%
controls:12.00%
—
—
—
—
cases:9.38%
controls:3.00%
cases:25.53%
controls:12.84%
cases:28.92%
controls:16.84%
21
134
75
826
21
116
76
851
—
—
9
29
87
937
24
123
70
835
24
145
59
716
Counselling and guidance related to nutrition and weight management
SPAT1306 [2001700407]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:1.25%
—
—
—
—
—
—
—
—
—
—
—
—
0
12
96
948
—
—
—
—
—
—
paracetamol, combinations excl. psycholeptics
N02BE51 [21604348]
—
—
—
—
—
—
1.0e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:7.23%
controls:2.79%
—
—
—
—
—
—
6
24
77
837
Oxygen [Partial pressure] in Venous blood
2705-2 [3024354]
-1.0e+50
—
—
—
—
—
1.7e+00
cases:0.00%
controls:0.52%
—
—
—
—
—
—
—
—
—
—
cases:6.02%
controls:1.16%
0
5
96
955
—
—
—
—
—
5
10
78
851
Horse dander IgE Ab [Units/volume] in Serum
6143-2 [3010726]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.52%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
96
955
—
—
—
—
—
—
fentanyl; nasal, sublingual, transdermal
N02AB03 [21604272]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.93%
—
—
—
—
—
—
0
8
83
853
Other and unspecified ventral hernia without obstruction or gangrene
K43.9 [45533594]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.52%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
96
955
—
—
—
—
—
—
Diabetes insulin dependent
T89 [2002001130]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.74%
—
—
—
—
—
—
0
15
83
846
SMOKING - SMOKE2: no - SMOKE3: former - SMOKE5: former
SMOKING-2-2-4 [2002330109]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:1.77%
—
—
—
—
—
—
—
—
—
—
—
—
0
17
96
943
—
—
—
—
—
—
Split tooth for reasons other than trauma
K03.82 [2000502700]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.52%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
96
955
—
—
—
—
—
—
Other somatoform disorders
F45.8 [45600750]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.93%
—
—
—
—
—
—
0
8
83
853
Influenza virus A and B and SARS-CoV-2 (COVID-19) and Respiratory syncytial virus RNA panel - Respiratory system specimen by NAA with probe detection
95941-1 [36031861]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.70%
—
—
—
—
—
—
0
6
83
855
Buprenorphine [Presence] in Urine by Screen method
93494-3 [1001926]
-1.0e+50
—
—
—
—
—
-1.0e+50
cases:0.00%
controls:0.63%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.70%
0
6
96
954
—
—
—
—
—
0
6
83
855
Elevated blood pressure
K85 [2002000612]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.63%
—
—
—
—
—
—
—
0
6
94
952
—
Bipolar affective disorder, unspecified
F31.9 [45571758]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.93%
—
—
—
—
—
—
0
8
83
853
Type 1 diabetes mellitus, With renal complications
E10.2 [45586137]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.52%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
96
955
—
—
—
—
—
—
Excision of skin or mucous membrane lesion
SPAT1141 [2001700242]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.93%
—
—
—
—
—
—
0
8
83
853
Health maint/preventive medicine
A98 [2002000231]
-1.5e-01
-2.1e-01
—
—
—
-1.3e-01
1.5e-01
cases:20.83%
controls:23.33%
cases:14.43%
controls:17.27%
—
—
—
—
—
—
cases:17.02%
controls:18.89%
cases:43.37%
controls:39.84%
20
224
76
736
14
167
83
800
—
—
—
16
181
78
777
36
343
47
518
Limited function/disability NOS
A28 [2002000162]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:0.72%
—
—
—
—
—
—
—
—
—
—
—
0
7
97
960
—
—
—
—
—
triamcinolone; nasal
R01AD11 [21605052]
-1.0e+50
—
—
—
—
—
-1.0e+50
cases:0.00%
controls:0.63%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.70%
0
6
96
954
—
—
—
—
—
0
6
83
855
Pain in limb
M79.6 [45587063]
9.4e-01
—
—
—
—
—
1.3e-01
cases:8.33%
controls:3.44%
—
—
—
—
—
—
—
—
—
—
cases:7.23%
controls:6.39%
8
33
88
927
—
—
—
—
—
6
55
77
806
Leukocytes [Presence] in Urine
33052-2 [3045414]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.16%
—
—
—
—
—
—
0
10
83
851
Oxygen [Partial pressure] in Capillary blood
2704-5 [3028626]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.83%
—
—
—
—
—
—
—
—
—
—
—
—
0
8
96
952
—
—
—
—
—
—
Extensive body CT
JN4BD [2001310899]
—
-1.0e+50
—
—
—
-1.0e+50
—
—
—
cases:0.00%
controls:0.62%
—
—
—
—
—
—
cases:0.00%
controls:0.52%
—
—
—
0
6
97
961
—
—
—
0
5
94
953
—
Nuclear Ab [Titer] in Serum
29953-7 [3037522]
—
-1.0e+50
—
—
—
-1.0e+50
—
—
—
cases:0.00%
controls:0.62%
—
—
—
—
—
—
cases:0.00%
controls:0.52%
—
—
—
0
6
97
961
—
—
—
0
5
94
953
—
C reactive protein [Mass/volume] in Serum or Plasma by High sensitivity method
30522-7 [3010156]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.81%
—
—
—
—
—
—
0
7
83
854
Uroflowmetry
44856007 [4261340]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.94%
—
—
—
—
—
—
—
0
9
94
949
—
Other specified pulpit
K04.08 [2000502703]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.39%
—
—
—
—
—
—
0
12
83
849
sulfadiazine and trimethoprim
J01EE02 [21602962]
9.7e-01
—
—
—
—
—
—
cases:8.33%
controls:3.33%
—
—
—
—
—
—
—
—
—
—
—
—
8
32
88
928
—
—
—
—
—
—
Nonorganic insomnia
F51.0 [45552492]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:0.62%
—
—
—
—
—
—
—
—
—
—
—
0
6
97
961
—
—
—
—
—
Vomiting
D10 [2002000309]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.63%
—
—
—
—
—
—
—
0
6
94
952
—
desloratadine; oral
R06AX27 [21603526]
—
—
—
—
—
-1.0e+50
2.1e-01
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:2.40%
cases:7.23%
controls:5.92%
—
—
—
—
—
0
23
94
935
6
51
77
810
Nitrite [Presence] in Urine by Test strip
5802-4 [3021601]
2.6e-01
7.6e-01
—
—
—
1.1e+00
5.3e-02
cases:6.25%
controls:4.90%
cases:5.15%
controls:2.48%
—
—
—
—
—
—
cases:6.38%
controls:2.19%
cases:10.84%
controls:10.34%
6
47
90
913
5
24
92
943
—
—
—
6
21
88
937
9
89
74
772
goserelin; implant
L02AE03 [21603826]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.70%
—
—
—
—
—
—
0
6
83
855
azelastine; nasal
R01AC03 [21605035]
—
-1.0e+50
—
—
—
-1.0e+50
-1.0e+50
—
—
cases:0.00%
controls:1.86%
—
—
—
—
—
—
cases:0.00%
controls:1.77%
cases:0.00%
controls:3.95%
—
0
18
97
949
—
—
—
0
17
94
941
0
34
83
827
Fracture of tooth, open
S02.51 [45755762]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.52%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
96
955
—
—
—
—
—
—
Examination of eyes and vision
Z01.0 [45566391]
—
-1.0e+50
—
—
—
—
1.1e+00
—
—
cases:0.00%
controls:0.62%
—
—
—
—
—
—
—
—
cases:7.23%
controls:2.44%
—
0
6
97
961
—
—
—
—
6
21
77
840
pramipexole; oral
N04BC05 [21604477]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:0.72%
—
—
—
—
—
—
—
—
—
—
—
0
7
97
960
—
—
—
—
—
Partial excision of meniscus of knee, arthroscopic
NGD05 [2001308109]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.58%
—
—
—
—
—
—
0
5
83
856
Cholesterol in HDL [Moles/volume] in Serum or Plasma
14646-4 [3023602]
1.6e-01
5.3e-01
—
—
—
2.8e-01
2.7e-01
cases:12.50%
controls:10.83%
cases:10.31%
controls:6.31%
—
—
—
—
—
—
cases:9.57%
controls:7.41%
cases:31.33%
controls:25.78%
12
104
84
856
10
61
87
906
—
—
—
9
71
85
887
26
222
57
639
tretinoin, combinations; ointment
D10AD51 [21602298]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.94%
—
—
—
—
—
—
—
—
—
—
—
—
0
9
96
951
—
—
—
—
—
—
hydrocortisone; local oral
A01AC03 [21600036]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.93%
—
—
—
—
—
—
0
8
83
853
Hip extensive X-ray examination
NF1BA [2001307899]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.52%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
96
955
—
—
—
—
—
—
Chlamydia trachomatis DNA [Presence] in Urine by NAA with probe detection
6357-8 [3024950]
—
—
—
—
—
—
1.0e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:8.43%
controls:3.25%
—
—
—
—
—
—
7
28
76
833
prednisone; oral
H02AB07 [21602735]
—
—
—
—
—
—
1.5e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:6.02%
controls:1.39%
—
—
—
—
—
—
5
12
78
849
CBC panel - Blood by Automated count
58410-2 [40761511]
1.4e-01
4.3e-01
1.5e+00
—
9.5e-01
5.0e-01
3.1e-01
cases:18.75%
controls:16.77%
cases:16.49%
controls:11.38%
cases:7.22%
controls:1.65%
—
—
cases:5.21%
controls:2.07%
cases:19.15%
controls:12.53%
cases:38.55%
controls:31.59%
18
161
78
799
16
110
81
857
7
16
90
951
—
5
20
91
946
18
120
76
838
32
272
51
589
Acute sinusitis, unspecified
J01.9 [45543252]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.58%
—
—
—
—
—
—
0
5
83
856
mianserin; oral
N06AX03 [21604732]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.58%
—
—
—
—
—
—
0
5
83
856
Outcome of delivery
Z37 [45581024]
-3.1e-01
—
—
—
—
9.3e-01
2.2e-01
cases:5.21%
controls:6.98%
—
—
—
—
—
—
—
—
cases:6.38%
controls:2.61%
cases:8.43%
controls:6.85%
5
67
91
893
—
—
—
—
6
25
88
933
7
59
76
802
Single live birth
Z37.0 [45571346]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:0.83%
—
—
—
—
—
—
—
—
—
—
—
0
8
97
959
—
—
—
—
—
Chest pain NOS
A11 [2002000152]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.52%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
96
955
—
—
—
—
—
—
cetirizine; oral
R06AE07 [21603497]
2.3e-01
—
-1.0e+50
—
—
—
—
cases:9.38%
controls:7.60%
—
—
cases:0.00%
controls:0.52%
—
—
—
—
—
—
—
—
9
73
87
887
—
0
5
97
962
—
—
—
—
aripiprazole; oral, parenteral
N05AX12 [21604562]
-1.0e+50
-1.0e+50
—
—
—
-1.0e+50
-1.0e+50
cases:0.00%
controls:0.83%
cases:0.00%
controls:0.62%
—
—
—
—
—
—
cases:0.00%
controls:0.73%
cases:0.00%
controls:1.05%
0
8
96
952
0
6
97
961
—
—
—
0
7
94
951
0
9
83
852
Body height measure
50373000 [4177340]
-1.0e+00
—
—
—
—
—
1.0e+50
cases:10.42%
controls:23.96%
—
—
—
—
—
—
—
—
—
—
cases:13.25%
controls:0.00%
10
230
86
730
—
—
—
—
—
11
0
72
861
bimatoprost
S01EE03 [21603712]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.58%
—
—
—
—
—
—
0
5
83
856
Extraction of root of tooth
EBA30 [2001301929]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.52%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
96
955
—
—
—
—
—
—
ibuprofen
R02AX02 [1588667]
9.7e-03
-3.3e-01
-1.0e+50
—
-1.0e+50
-7.0e-01
-5.0e-01
cases:31.25%
controls:31.04%
cases:10.31%
controls:13.75%
cases:0.00%
controls:1.55%
—
—
cases:0.00%
controls:1.97%
cases:7.45%
controls:13.99%
cases:25.30%
controls:35.77%
30
298
66
662
10
133
87
834
0
15
97
952
—
0
19
96
947
7
134
87
824
21
308
62
553
Besnier prurigo
L20.0 [45562534]
-1.0e+50
—
—
—
—
-1.0e+50
-1.0e+50
cases:0.00%
controls:0.94%
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.84%
cases:0.00%
controls:1.51%
0
9
96
951
—
—
—
—
0
8
94
950
0
13
83
848
Cystitis, unspecified
N30.9 [45606488]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.52%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
96
955
—
—
—
—
—
—
Home Visit
OMOP4822459 [581476]
2.1e-01
—
—
—
—
5.3e-01
-2.5e-01
cases:5.21%
controls:4.27%
—
—
—
—
—
—
—
—
cases:6.38%
controls:3.86%
cases:7.23%
controls:9.06%
5
41
91
919
—
—
—
—
6
37
88
921
6
78
77
783
Atrial fibrillation and flutter
I48 [45596206]
4.8e-01
1.3e+00
—
—
—
8.2e-01
1.1e+00
cases:6.25%
controls:3.96%
cases:7.22%
controls:2.17%
—
—
—
—
—
—
cases:6.38%
controls:2.92%
cases:15.66%
controls:5.92%
6
38
90
922
7
21
90
946
—
—
—
6
28
88
930
13
51
70
810
Irrigation or wax removal of outer auditory canal
SPAT1033 [2001700134]
-1.0e+50
-1.0e+50
—
—
—
—
—
cases:0.00%
controls:1.15%
cases:0.00%
controls:0.52%
—
—
—
—
—
—
—
—
—
—
0
11
96
949
0
5
97
962
—
—
—
—
—
Implantation of transvenous cardiac pacemaker with atrial and ventricular electrodes
FPE20 [2001303170]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.70%
—
—
—
—
—
—
0
6
83
855
Pediatric Surgery
OMOP4822020 [45756819]
—
-1.0e+50
—
—
—
-1.0e+50
-1.0e+50
—
—
cases:0.00%
controls:0.52%
—
—
—
—
—
—
cases:0.00%
controls:0.63%
cases:0.00%
controls:0.81%
—
0
5
97
962
—
—
—
0
6
94
952
0
7
83
854
dapagliflozin; oral
A10BK01 [1123890]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.70%
—
—
—
—
—
—
0
6
83
855
Immunoglobulin A (IgA) nephropathy
N08.2*D89.80 [2000503126]
—
1.0e+50
1.0e+50
1.0e+50
1.0e+50
1.0e+50
1.0e+50
—
—
cases:28.87%
controls:0.00%
cases:16.49%
controls:0.00%
cases:6.19%
controls:0.00%
cases:14.58%
controls:0.00%
cases:27.66%
controls:0.00%
cases:34.94%
controls:0.00%
—
28
0
69
967
16
0
81
967
6
0
91
967
14
0
82
966
26
0
68
958
29
0
54
861
Low back symptom/complaint
L03 [2002000628]
—
—
—
—
—
—
5.0e-01
—
—
—
—
—
—
—
—
—
—
—
—
cases:7.23%
controls:4.53%
—
—
—
—
—
—
6
39
77
822
Adaptation disorder with mixed anxiety and depression
F43.22 [2000502003]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.81%
—
—
—
—
—
—
0
7
83
854
dexamethasone and antiinfectives
S02CA06 [21605178]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:0.72%
—
—
—
—
—
—
—
—
—
—
—
0
7
97
960
—
—
—
—
—
Calcium.ionized [Moles/volume] in Venous blood
41645-3 [3033705]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.58%
—
—
—
—
—
—
0
5
83
856
valdecoxib; oral
M01AH03 [21603994]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.73%
—
—
—
—
—
—
—
—
—
—
—
—
0
7
96
953
—
—
—
—
—
—
Caries limited to enamel
K02.0 [45576967]
-1.0e+50
—
—
—
—
-1.0e+50
—
cases:0.00%
controls:1.56%
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.63%
—
—
0
15
96
945
—
—
—
—
0
6
94
952
—
Type 1 diabetes mellitus, With multiple complications
E10.7 [45571655]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.83%
—
—
—
—
—
—
—
—
—
—
—
—
0
8
96
952
—
—
—
—
—
—
Opiates [Presence] in Urine
3879-4 [3027008]
-1.0e+50
—
—
—
—
-1.0e+50
—
cases:0.00%
controls:0.83%
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.52%
—
—
0
8
96
952
—
—
—
—
0
5
94
953
—
Sickle-cell anaemia without crisis
D57.1 [45542709]
—
—
—
1.0e+50
—
1.0e+50
1.0e+50
—
—
—
—
—
—
cases:7.22%
controls:0.00%
—
—
cases:7.45%
controls:0.00%
cases:8.43%
controls:0.00%
—
—
—
7
0
90
967
—
7
0
87
958
7
0
76
861
Pregnancy high risk
W84 [2002001275]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.63%
—
—
—
—
—
—
—
—
—
—
—
—
0
6
96
954
—
—
—
—
—
—
pregabalin; oral
N02BF02 [955152]
—
—
—
—
—
1.1e+00
4.2e-01
—
—
—
—
—
—
—
—
—
—
cases:5.32%
controls:1.88%
cases:7.23%
controls:4.88%
—
—
—
—
—
5
18
89
940
6
42
77
819
General and Unspecified, Medical examin/health eval partial
A31 [2002000165]
-1.0e+50
—
—
—
—
—
-1.0e+50
cases:0.00%
controls:0.52%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.70%
0
5
96
955
—
—
—
—
—
0
6
83
855
General counselling and advice on contraception
Z30.0 [45537624]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.52%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
96
955
—
—
—
—
—
—
Health check-up of pregnant person
SPAT1379 [2001700479]
—
—
-1.0e+50
—
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.52%
—
—
cases:0.00%
controls:0.52%
—
—
—
—
—
—
0
5
97
962
—
0
5
96
961
—
—
Tissue Pathology biopsy report
66121-5 [40768804]
1.1e+00
—
—
—
—
—
1.5e-01
cases:9.38%
controls:3.23%
—
—
—
—
—
—
—
—
—
—
cases:7.23%
controls:6.27%
9
31
87
929
—
—
—
—
—
6
54
77
807
Hypothyroidism/myxoedema
T86 [2002001128]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.28%
—
—
—
—
—
—
0
11
83
850
Coloscopy
UJF32 [2001305029]
1.4e+00
—
—
1.0e+50
—
1.8e+00
—
cases:8.33%
controls:2.29%
—
—
—
—
cases:10.31%
controls:0.00%
—
—
cases:5.32%
controls:0.94%
—
—
8
22
88
938
—
—
10
0
87
967
—
5
9
89
949
—
prednisolone
A07EA01 [21600653]
7.5e-01
—
—
—
—
9.1e-01
4.6e-01
cases:15.63%
controls:8.02%
—
—
—
—
—
—
—
—
cases:7.45%
controls:3.13%
cases:13.25%
controls:8.83%
15
77
81
883
—
—
—
—
7
30
87
928
11
76
72
785
Hip symptom/complaint
L13 [2002000637]
-1.0e+50
—
—
—
—
-1.0e+50
—
cases:0.00%
controls:0.63%
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.15%
—
—
0
6
96
954
—
—
—
—
0
11
94
947
—
Subjective visual disturbances
H53.1 [45557467]
-1.0e+50
—
—
—
—
—
-1.0e+50
cases:0.00%
controls:0.52%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.70%
0
5
96
955
—
—
—
—
—
0
6
83
855
Dental calculus supragingival
K03.64 [2000502689]
4.3e-01
—
—
—
—
—
1.1e+00
cases:5.21%
controls:3.44%
—
—
—
—
—
—
—
—
—
—
cases:10.84%
controls:4.07%
5
33
91
927
—
—
—
—
—
9
35
74
826
chorionic gonadotrophin; parenteral
G03GA01 [21602599]
—
—
—
—
—
-1.0e+50
-1.0e+50
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.52%
cases:0.00%
controls:1.16%
—
—
—
—
—
0
5
94
953
0
10
83
851
Body mass index
60621009 [4245997]
-1.0e+00
—
—
—
—
—
1.0e+50
cases:10.42%
controls:23.96%
—
—
—
—
—
—
—
—
—
—
cases:13.25%
controls:0.00%
10
230
86
730
—
—
—
—
—
11
0
72
861
sitagliptin; oral
A10BH01 [21600784]
1.4e+00
1.6e+00
—
—
—
1.3e+00
1.2e+00
cases:5.21%
controls:1.35%
cases:5.15%
controls:1.03%
—
—
—
—
—
—
cases:5.32%
controls:1.46%
cases:7.23%
controls:2.21%
5
13
91
947
5
10
92
957
—
—
—
5
14
89
944
6
19
77
842
pivmecillinam; oral
J01CA08 [21602827]
-6.6e-02
—
—
—
—
5.9e-01
5.1e-01
cases:8.33%
controls:8.85%
—
—
—
—
—
—
—
—
cases:5.32%
controls:3.03%
cases:14.46%
controls:9.18%
8
85
88
875
—
—
—
—
5
29
89
929
12
79
71
782
Myelocytes/Leukocytes in Blood
26498-6 [3017181]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.93%
—
—
—
—
—
—
0
8
83
853
Glaucoma suspect
H40.0 [45567051]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.83%
—
—
—
—
—
—
—
—
—
—
—
—
0
8
96
952
—
—
—
—
—
—
Other chronic obstructive pulmonary disease
J44 [45543268]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.58%
—
—
—
—
—
—
0
5
83
856
Pain in joint
M25.5 [45586941]
9.1e-01
—
—
—
—
—
5.1e-01
cases:6.25%
controls:2.60%
—
—
—
—
—
—
—
—
—
—
cases:6.02%
controls:3.72%
6
25
90
935
—
—
—
—
—
5
32
78
829
Other specified counselling
Z71.8 [45581061]
—
—
—
—
—
—
3.6e-01
—
—
—
—
—
—
—
—
—
—
—
—
cases:6.02%
controls:4.30%
—
—
—
—
—
—
5
37
78
824
SARS-CoV-2 (COVID-19) RNA [Presence] in Respiratory system specimen by NAA with probe detection
94500-6 [706163]
-2.1e-02
3.1e-01
-1.0e+50
—
—
—
3.5e-01
cases:5.21%
controls:5.31%
cases:5.15%
controls:3.83%
cases:0.00%
controls:0.83%
—
—
—
—
—
—
cases:15.66%
controls:11.61%
5
51
91
909
5
37
92
930
0
8
97
959
—
—
—
13
100
70
761
Neoplasm of uncertain or unknown behaviour: Skin
D48.5 [45586113]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.52%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
96
955
—
—
—
—
—
—
ferrous sulfate; oral
B03AA07 [21601086]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.58%
—
—
—
—
—
—
0
5
83
856
Cancer Ag 15-3 [Units/volume] in Serum or Plasma
6875-9 [3006588]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.52%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
96
955
—
—
—
—
—
—
Acute spinal anesthesia for delivery
WX321 [2001310800]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:1.15%
—
—
—
—
—
—
—
—
—
—
—
—
0
11
96
949
—
—
—
—
—
—
Acute bronchitis, unspecified
J20.9 [45562445]
—
-1.0e+50
—
—
—
—
1.4e+00
—
—
cases:0.00%
controls:0.52%
—
—
—
—
—
—
—
—
cases:9.64%
controls:2.44%
—
0
5
97
962
—
—
—
—
8
21
75
840
diclofenac
D11AX18 [21602355]
1.1e+00
—
—
—
—
—
—
cases:5.21%
controls:1.77%
—
—
—
—
—
—
—
—
—
—
—
—
5
17
91
943
—
—
—
—
—
—
X-ray examination of the lungs in one projection
GD1PA [2001303645]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:0.72%
—
—
—
—
—
—
—
—
—
—
—
0
7
97
960
—
—
—
—
—
Counselling and guidance related to ageing
SPAT1304 [2001700405]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.28%
—
—
—
—
—
—
0
11
83
850
Intravenous general anesthesia
WX404 [2001310807]
—
—
—
—
—
-1.0e+50
1.4e+00
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.04%
cases:6.02%
controls:1.63%
—
—
—
—
—
0
10
94
948
5
14
78
847
Treponema pallidum Ab [Presence] in Serum
22587-0 [3019832]
-1.0e+50
1.5e+00
—
—
—
—
6.6e-01
cases:0.00%
controls:2.40%
cases:5.15%
controls:1.24%
—
—
—
—
—
—
—
—
cases:8.43%
controls:4.53%
0
23
96
937
5
12
92
955
—
—
—
—
7
39
76
822
Epilepsy
G40 [45595935]
-1.0e+50
—
—
—
—
—
-1.0e+50
cases:0.00%
controls:0.73%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.58%
0
7
96
953
—
—
—
—
—
0
5
83
856
Insertion or removal of intrauterine contraceptive device
SPAT1190 [2001700291]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.94%
—
—
—
—
—
—
—
—
—
—
—
—
0
9
96
951
—
—
—
—
—
—
Dry eye syndrome
H04.10 [2000502254]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.28%
—
—
—
—
—
—
0
11
83
850
choriogonadotropin alfa; parenteral
G03GA08 [21602606]
—
—
—
—
—
-1.0e+50
-1.0e+50
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.52%
cases:0.00%
controls:1.16%
—
—
—
—
—
0
5
94
953
0
10
83
851
Low back pain
M54.5 [45553207]
5.7e-01
—
—
—
—
—
-2.3e-02
cases:5.21%
controls:3.02%
—
—
—
—
—
—
—
—
—
—
cases:6.02%
controls:6.16%
5
29
91
931
—
—
—
—
—
5
53
78
808
Seborrhoeic keratosis
L82 [45548208]
-1.0e+50
—
—
—
—
-1.0e+50
-1.0e+50
cases:0.00%
controls:1.25%
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.52%
cases:0.00%
controls:1.74%
0
12
96
948
—
—
—
—
0
5
94
953
0
15
83
846
General examination of pregnant woman
XMA22 [2001306916]
-1.0e+50
—
—
—
—
—
-1.0e+50
cases:0.00%
controls:0.63%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.81%
0
6
96
954
—
—
—
—
—
0
7
83
854
Delivery in a completely normal case[PARTUS SINE COMPLICATIONE]
6500B [2000405100]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.73%
—
—
—
—
—
—
—
—
—
—
—
—
0
7
96
953
—
—
—
—
—
—
Screening procedure
SPAT1324 [2001700425]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:0.72%
—
—
—
—
—
—
—
—
—
—
—
0
7
97
960
—
—
—
—
—
Leg/thigh symptom/complaint
L14 [2002000638]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.52%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
96
955
—
—
—
—
—
—
Primary coxarthrosis, bilateral
M16.0 [45543482]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:0.52%
—
—
—
—
—
—
—
—
—
—
—
0
5
97
962
—
—
—
—
—
Conjunctivitis
H10 [45581570]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.63%
—
—
—
—
—
—
—
—
—
—
—
—
0
6
96
954
—
—
—
—
—
—
tizanidine; oral
M03BX02 [21604116]
2.2e-01
8.2e-01
—
—
-1.0e+50
—
-7.8e-02
cases:13.54%
controls:11.15%
cases:7.22%
controls:3.31%
—
—
—
—
cases:0.00%
controls:0.62%
—
—
cases:9.64%
controls:10.34%
13
107
83
853
7
32
90
935
—
—
0
6
96
960
—
8
89
75
772
glimepiride; oral
A10BB12 [21600761]
1.1e+00
—
-1.0e+50
—
—
-1.0e+50
-1.0e+50
cases:5.21%
controls:1.77%
—
—
cases:0.00%
controls:0.72%
—
—
—
—
cases:0.00%
controls:1.46%
cases:0.00%
controls:1.28%
5
17
91
943
—
0
7
97
960
—
—
0
14
94
944
0
11
83
850
Glucose [Moles/volume] in Serum or Plasma --2 hours post meal
14761-1 [3012413]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.70%
—
—
—
—
—
—
0
6
83
855
Coxarthrosis, unspecified
M16.9 [45591742]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.63%
—
—
—
—
—
—
—
—
—
—
—
—
0
6
96
954
—
—
—
—
—
—
rubella, live attenuated
J07BJ01 [21601359]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:0.83%
—
—
—
—
—
—
—
—
—
—
—
0
8
97
959
—
—
—
—
—
dexamethasone and antiinfectives
S01CA01 [21603652]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:0.52%
—
—
—
—
—
—
—
—
—
—
—
0
5
97
962
—
—
—
—
—
lamotrigine; oral
N03AX09 [21604431]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:0.52%
—
—
—
—
—
—
—
—
—
—
—
0
5
97
962
—
—
—
—
—
Thyroxine (T4) free [Moles/volume] in Serum or Plasma
14920-3 [3008486]
1.4e-01
1.3e-01
—
—
—
-1.6e-01
1.2e-01
cases:11.46%
controls:10.10%
cases:6.19%
controls:5.48%
—
—
—
—
—
—
cases:5.32%
controls:6.16%
cases:22.89%
controls:20.79%
11
97
85
863
6
53
91
914
—
—
—
5
59
89
899
19
179
64
682
Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI)/1.73 sq M
62238-1 [40764999]
-6.2e-01
6.1e-01
1.7e+00
—
1.2e+00
3.9e-01
4.2e-01
cases:6.25%
controls:11.04%
cases:14.43%
controls:8.38%
cases:6.19%
controls:1.24%
—
—
cases:5.21%
controls:1.66%
cases:13.83%
controls:9.81%
cases:28.92%
controls:21.02%
6
106
90
854
14
81
83
886
6
12
91
955
—
5
16
91
950
13
94
81
864
24
181
59
680
General and Unspecified, Preventive immunization/medic
A44 [2002000178]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.63%
—
—
—
—
—
—
0
14
83
847
Other disorders of vitreous body
H43.8 [45533329]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.52%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
96
955
—
—
—
—
—
—
dexchlorpheniramine, combinations
R06AB52 [21603467]
-1.0e+50
—
—
—
—
—
-1.0e+50
cases:0.00%
controls:0.83%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.16%
0
8
96
952
—
—
—
—
—
0
10
83
851
Psychiatry
26 [38004469]
2.6e-01
—
—
—
—
9.3e-01
4.4e-01
cases:6.25%
controls:4.90%
—
—
—
—
—
—
—
—
cases:6.38%
controls:2.61%
cases:8.43%
controls:5.57%
6
47
90
913
—
—
—
—
6
25
88
933
7
48
76
813
Sleep apnoea
G47.3 [45562094]
1.0e+00
—
—
—
—
1.3e+00
1.0e+00
cases:6.25%
controls:2.29%
—
—
—
—
—
—
—
—
cases:5.32%
controls:1.46%
cases:9.64%
controls:3.72%
6
22
90
938
—
—
—
—
5
14
89
944
8
32
75
829
risperidone; oral, parenteral
N05AX08 [21604559]
-1.0e+50
—
—
—
—
—
-1.0e+50
cases:0.00%
controls:0.73%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.16%
0
7
96
953
—
—
—
—
—
0
10
83
851
Supervision of other high-risk pregnancies
Z35.8 [45552076]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.83%
—
—
—
—
—
—
—
—
—
—
—
—
0
8
96
952
—
—
—
—
—
—
lansoprazole; oral
A02BC03 [21600098]
7.7e-01
—
-1.0e+50
—
—
—
—
cases:10.42%
controls:5.10%
—
—
cases:0.00%
controls:0.52%
—
—
—
—
—
—
—
—
10
49
86
911
—
0
5
97
962
—
—
—
—
Preparing and fitting the occlusal splint in the mouth
SHB00 [2001310410]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.52%
—
—
—
—
—
—
—
0
5
94
953
—
Type 1 diabetes mellitus, Without complications
E10.9 [45581351]
-1.0e+50
-1.0e+50
-1.0e+50
—
—
-1.0e+50
—
cases:0.00%
controls:1.67%
cases:0.00%
controls:0.93%
cases:0.00%
controls:0.72%
—
—
—
—
cases:0.00%
controls:0.84%
—
—
0
16
96
944
0
9
97
958
0
7
97
960
—
—
0
8
94
950
—
Respiratory infection other
R83 [2002000951]
-1.0e+50
—
—
—
—
—
6.1e-01
cases:0.00%
controls:1.56%
—
—
—
—
—
—
—
—
—
—
cases:6.02%
controls:3.37%
0
15
96
945
—
—
—
—
—
5
29
78
832
dexamethasone
S01BA01 [21603618]
—
-1.0e+50
—
—
—
-1.0e+50
—
—
—
cases:0.00%
controls:0.52%
—
—
—
—
—
—
cases:0.00%
controls:0.84%
—
—
—
0
5
97
962
—
—
—
0
8
94
950
—
Constipation, unspecified
K59.09 [2000502926]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.70%
—
—
—
—
—
—
0
6
83
855
Malignant neoplasm of prostate
C61 [45547509]
-1.0e+50
-1.0e+50
—
—
—
—
—
cases:0.00%
controls:1.04%
cases:0.00%
controls:0.83%
—
—
—
—
—
—
—
—
—
—
0
10
96
950
0
8
97
959
—
—
—
—
—

LabWAS

↥
OMOP Concept
People with measurements
Mean N measurements
Mean measured value
(ID) Name
N Cases
N Controls
OR
-log10(p)
cases
controls
cases
controls
unit
-log10(p)
N cases
N controls
35
65
7.82
19.77
13.4
2.7
90.50
67.20
e9/l
1.64
22
49
15
0
+∞
16.07
2.2
0.0
—
—
—
0
0
40
133
4.39
11.17
5.7
2.9
3.27
2.00
e6/l
0.21
18
67
57
249
4.08
10.80
7.8
2.9
1.19
0.38
e6/l
0.42
45
178
55
235
4.05
10.75
10.6
3.3
196.09
64.91
mg/l
1.06
50
152
54
229
4.02
10.64
22.0
3.5
7.39
7.40
ph
0.57
43
162
15
8
21.80
10.64
2.6
1.6
—
—
—
0
0
10
0
+∞
10.60
4.3
0.0
—
—
—
0
0
49
197
3.97
10.38
11.6
4.1
92.84
90.76
%
0.21
49
192
54
237
3.85
9.96
8.1
2.8
—
—
estimate
—
0
0
61
296
3.81
9.56
9.2
3.1
41.95
63.32
e6/l
0.35
52
221
17
17
11.83
9.48
2.2
1.1
141.60
210.00
au/ml
—
5
5
12
5
27.01
9.15
1.0
1.6
—
—
—
0
0
17
19
10.57
8.98
2.2
1.3
—
—
—
0
0
29
88
4.26
8.93
13.8
4.4
7.35
7.39
ph
1.89
18
54
8
0
+∞
8.45
7.1
0.0
5.97
—
mmol/l
—
8
0
27
82
4.16
8.26
17.4
7.8
—
—
—
0
0
70
397
3.67
8.13
30.1
7.1
1.21
1.21
mmol/l
0.14
65
348
30
101
3.84
7.93
4.1
1.4
—
—
—
0
0
62
337
3.29
7.51
12.4
3.9
112.07
89.52
e6/l
0.11
52
226
63
347
3.28
7.43
2.5
2.0
96.83
99.39
pmol/l
0.14
33
179
35
136
3.45
7.41
3.8
1.6
—
—
—
0
0
18
31
6.86
7.35
1.5
1.3
—
—
—
0
0
30
107
3.60
7.23
10.2
7.4
103.70
103.98
mmol/l
0.10
30
107
21
60
4.18
6.89
14.1
10.7
25.30
25.40
mmol/l
0.04
21
60
51
257
3.05
6.88
7.3
2.3
—
—
—
0
0
12
12
11.20
6.75
1.2
1.0
—
—
—
0
0
52
277
2.87
6.17
17.1
6.1
—
—
—
0
0
13
20
7.31
5.78
10.2
4.8
76.77
65.13
%
1.00
13
20
38
178
2.85
5.64
3.8
2.0
—
—
—
0
0
10
12
9.13
5.20
9.7
6.4
10.55
10.41
%
—
10
12
18
56
3.71
5.20
2.0
1.2
—
—
—
0
0
60
366
2.65
5.17
21.6
11.1
0.03
0.00
e9/l
1.16
48
292
71
475
2.80
5.01
21.5
10.3
4.29
4.36
e9/l
0.08
64
415
45
243
2.58
4.94
5.1
4.4
—
—
—
0
0
47
261
2.54
4.84
11.9
5.7
—
—
—
0
0
24
94
3.06
4.83
8.4
7.1
7.40
7.41
ph
0.24
11
56
60
375
2.55
4.79
7.5
2.6
—
—
estimate
—
0
0
19
66
3.33
4.64
2.5
1.4
—
—
—
0
0
41
218
2.51
4.58
3.5
2.2
3.37
2.81
mg/l
0.82
36
198
24
100
2.85
4.31
1.9
1.4
—
—
—
0
0
63
416
2.44
4.27
16.9
6.4
0.58
0.57
e9/l
0.12
56
359
63
417
2.43
4.24
16.9
6.4
0.04
0.04
e9/l
0.01
56
357
81
610
2.89
4.03
16.8
7.8
82.86
80.52
u/l
0.11
76
575
23
97
2.79
4.02
8.7
7.0
-0.55
1.01
mmol/l
0.66
17
77
26
117
2.66
4.02
1.5
1.9
—
—
—
0
0
66
453
2.40
3.99
8.9
3.8
0.21
0.00
estimate
0.47
14
89
66
454
2.39
3.95
8.7
3.7
0.00
0.00
estimate
-0.00
14
99
57
370
2.29
3.89
21.1
13.0
1.35
1.23
inr
0.71
52
303
63
428
2.32
3.84
17.3
6.4
1.81
1.88
e9/l
0.26
56
381
65
449
2.33
3.79
8.9
3.7
0.07
0.00
estimate
0.47
14
97
63
433
2.27
3.67
17.3
7.0
0.19
0.19
e9/l
0.03
57
378
57
377
2.22
3.64
8.5
3.3
6.44
6.13
ph
0.85
24
200
28
141
2.38
3.39
1.8
1.8
1046.27
1252.31
nmol/l
0.70
22
110
40
235
2.19
3.37
1.7
1.5
—
—
—
0
0
31
165
2.29
3.31
4.8
3.6
28.54
277.35
ng/l
0.78
26
121
7
13
5.70
2.92
1.1
1.2
—
—
—
0
0
47
308
2.01
2.87
3.0
2.0
—
—
—
0
0
6
11
5.73
2.58
2.8
5.5
3809.00
784.27
mg
—
6
11
6
12
5.25
2.44
1.2
1.0
—
—
—
0
0
6
13
4.84
2.31
1.5
1.4
—
—
—
0
0
6
13
4.84
2.31
1.5
1.4
—
—
—
0
0
6
13
4.84
2.31
1.5
1.4
—
—
—
0
0
6
13
4.84
2.31
1.5
1.4
—
—
—
0
0
38
251
1.84
2.14
4.2
3.2
—
—
—
0
0
5
10
5.20
2.09
1.8
1.6
—
—
—
0
0
38
255
1.80
2.01
3.5
2.4
72.03
55.34
u/l
1.96
38
237
8
29
2.91
1.83
1.0
1.8
0.24
0.24
g/l
—
8
29
8
29
2.91
1.83
1.0
1.9
1.25
1.19
g/l
—
8
29
79
673
1.90
1.71
54.7
19.2
14.74
13.56
%
5.97
79
667
18
99
2.00
1.71
2.3
1.7
—
—
—
0
0
5
14
3.70
1.63
1.2
1.4
—
—
—
0
0
5
14
3.70
1.63
1.2
1.0
—
—
—
0
0
19
294
0.56
1.44
3.8
3.3
—
—
—
0
0
11
54
2.17
1.39
2.5
2.7
64.05
65.73
g/l
0.18
11
49
6
24
2.59
1.32
2.5
1.9
—
—
—
0
0
17
101
1.83
1.30
1.5
1.2
—
—
—
0
0
5
19
2.72
1.23
1.0
1.2
—
—
—
0
0
5
19
2.72
1.23
2.6
1.2
—
—
—
0
0
8
40
2.09
1.15
1.8
1.3
—
—
—
0
0
14
82
1.83
1.12
1.3
1.5
—
—
—
0
0
28
200
1.56
1.10
8.1
3.6
1.01
1.02
kg/l
1.21
21
124
5
21
2.45
1.10
2.8
1.2
—
58.00
—
0
5
5
22
2.34
1.04
2.0
1.5
—
—
—
0
0
12
73
1.73
0.86
9.9
2.9
0.01
1.41
e6/l
0.60
12
68
41
336
1.38
0.78
8.0
3.8
0.20
0.00
estimate
—
10
78
87
811
1.65
0.78
31.0
13.8
—
—
—
0
0
5
23
2.23
0.77
2.0
1.6
—
—
—
0
0
5
23
2.23
0.77
2.0
1.1
—
—
—
0
0
32
252
1.40
0.77
8.6
3.7
0.00
0.01
estimate
0.49
11
88
7
41
1.76
0.71
16.6
6.5
—
—
—
0
0
13
89
1.53
0.61
1.8
1.3
—
—
—
0
0
8
52
1.59
0.61
2.3
3.7
—
—
—
0
0
0
21
0.00
0.61
0.0
5.3
—
34.36
—
0
14
8
54
1.52
0.59
3.1
3.6
4.44
4.64
pmol/l
—
8
45
7
45
1.60
0.50
1.1
1.2
—
—
—
0
0
12
86
1.45
0.47
2.0
1.2
—
—
—
0
0
28
247
1.19
0.26
8.6
3.6
0.00
0.00
estimate
-0.00
11
81
24
212
1.17
0.22
1.2
1.4
0.82
2.88
u/ml
—
6
50
0
11
0.00
0.21
0.0
1.3
—
—
—
0
0
0
11
0.00
0.21
0.0
1.5
—
—
—
0
0
0
11
0.00
0.21
0.0
1.1
—
—
—
0
0
0
10
0.00
0.21
0.0
2.8
—
—
—
0
0
0
12
0.00
0.21
0.0
1.3
—
2.12
—
0
7
0
13
0.00
0.21
0.0
1.3
—
—
—
0
0
0
13
0.00
0.21
0.0
1.2
—
—
—
0
0
0
13
0.00
0.21
0.0
2.5
—
—
—
0
0
0
14
0.00
0.20
0.0
1.1
—
—
—
0
0
0
14
0.00
0.20
0.0
1.4
—
—
—
0
0
8
71
1.14
0.16
10.4
3.6
—
—
—
0
0
29
266
1.13
0.16
4.7
3.9
—
—
—
0
0
20
179
1.15
0.15
8.3
5.4
—
—
—
0
0
12
137
0.86
0.13
1.3
1.3
4.16
6.44
u/ml
—
7
47
62
602
1.08
0.09
4.9
4.4
14.44
14.95
pmol/l
0.80
57
546
9
86
1.05
0.07
1.3
1.2
—
—
—
0
0
33
319
1.05
0.04
4.2
3.7
23.35
25.43
ng/l
0.18
26
227
20
190
1.07
0.04
1.9
1.5
2.36
2.80
g/l
0.38
11
102
10
107
0.93
0.02
1.0
1.6
—
—
—
0
0
0
6
0.00
-0.00
0.0
2.8
—
—
—
0
0
7
71
0.98
-0.00
13.9
5.4
7.23
7.32
ph
—
7
49
0
6
0.00
-0.00
0.0
1.2
—
67.67
—
0
6
0
5
0.00
-0.00
0.0
1.2
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.4
—
7.30
—
0
5
9
93
0.96
-0.00
1.7
1.4
—
—
—
0
0
0
7
0.00
-0.00
0.0
1.1
—
—
—
0
0
0
5
0.00
-0.00
0.0
2.4
—
29.60
—
0
5

Mortality – FinRegistry

↥

Association

Association between endpoint D3_SICKLECELLDIS and mortality.

Females

Parameter HR [95% CI] p-value
D3_SICKLECELLDIS 1.674 [1.26, 2.22] < 0.001
Birth year 0.99 [0.98, 1.0] 0.031

During the follow-up period (1.1.1998 — 31.12.2019), 91 out of 347 females with D3_SICKLECELLDIS died.

Males

Parameter HR [95% CI] p-value
D3_SICKLECELLDIS 2.204 [1.57, 3.09] < 0.001
Birth year 0.988 [0.98, 1.0] 0.011

During the follow-up period (1.1.1998 — 31.12.2019), 96 out of 302 males with D3_SICKLECELLDIS died.

Mortality risk

Mortality risk for people of age

years, who have D3_SICKLECELLDIS.

N-year risk Females Males
1 0.132% 0.379%
5 0.85% 2.853%
10 2.005% 6.648%
15 3.874% 12.489%
20 6.564% 20.377%

Relationships between endpoints

↥

Index endpoint: D3_SICKLECELLDIS – Sickle-cell disorders

GWS hits: -

Endpoint
Case Overlap
Survival Analysis
Genetic Correlations
Genetic Signals
N (Jaccard index)
HR [CI]
rg [CI]
Hits
Coloc Hits
FinRegistry
FinnGen
FinRegistry
FinnGen
FinnGen
loading spinner Loading data